CN107412765A - People's Rotavirus Vaccine and preparation method thereof - Google Patents
People's Rotavirus Vaccine and preparation method thereof Download PDFInfo
- Publication number
- CN107412765A CN107412765A CN201710278659.7A CN201710278659A CN107412765A CN 107412765 A CN107412765 A CN 107412765A CN 201710278659 A CN201710278659 A CN 201710278659A CN 107412765 A CN107412765 A CN 107412765A
- Authority
- CN
- China
- Prior art keywords
- rotavirus
- polysaccharide
- protein
- vaccine
- people
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940124859 Rotavirus vaccine Drugs 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 150000004676 glycans Polymers 0.000 claims abstract description 173
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 166
- 239000005017 polysaccharide Substances 0.000 claims abstract description 165
- 241000702670 Rotavirus Species 0.000 claims abstract description 61
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 56
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 56
- 108700010850 rotavirus proteins Proteins 0.000 claims abstract description 18
- 230000008878 coupling Effects 0.000 claims abstract description 13
- 238000010168 coupling process Methods 0.000 claims abstract description 13
- 238000005859 coupling reaction Methods 0.000 claims abstract description 13
- 239000002105 nanoparticle Substances 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 61
- 102000004169 proteins and genes Human genes 0.000 claims description 39
- 239000000427 antigen Substances 0.000 claims description 32
- 108091007433 antigens Proteins 0.000 claims description 32
- 102000036639 antigens Human genes 0.000 claims description 32
- 241000700605 Viruses Species 0.000 claims description 22
- 229960000814 tetanus toxoid Drugs 0.000 claims description 17
- 241000617996 Human rotavirus Species 0.000 claims description 14
- 206010035664 Pneumonia Diseases 0.000 claims description 14
- 239000006249 magnetic particle Substances 0.000 claims description 14
- 108010052285 Membrane Proteins Proteins 0.000 claims description 12
- 102000018697 Membrane Proteins Human genes 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 239000002861 polymer material Substances 0.000 claims description 7
- 201000005702 Pertussis Diseases 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 4
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 239000011805 ball Substances 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000011806 microball Substances 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 abstract description 129
- 239000004005 microsphere Substances 0.000 abstract description 70
- 108010060123 Conjugate Vaccines Proteins 0.000 abstract description 32
- 229940031670 conjugate vaccine Drugs 0.000 abstract description 30
- 238000005516 engineering process Methods 0.000 abstract description 23
- 230000028993 immune response Effects 0.000 abstract description 16
- 230000002045 lasting effect Effects 0.000 abstract description 9
- 150000004804 polysaccharides Polymers 0.000 abstract description 6
- 101100394237 Mus musculus Hand1 gene Proteins 0.000 abstract description 2
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 34
- 230000000694 effects Effects 0.000 description 32
- 241000894006 Bacteria Species 0.000 description 27
- 239000000243 solution Substances 0.000 description 25
- 201000010099 disease Diseases 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 230000001580 bacterial effect Effects 0.000 description 23
- 239000003814 drug Substances 0.000 description 21
- 208000015181 infectious disease Diseases 0.000 description 21
- 230000005847 immunogenicity Effects 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 230000001717 pathogenic effect Effects 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 238000011161 development Methods 0.000 description 16
- 230000018109 developmental process Effects 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 239000002245 particle Substances 0.000 description 14
- 230000001681 protective effect Effects 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 238000000926 separation method Methods 0.000 description 13
- 201000009906 Meningitis Diseases 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 244000052769 pathogen Species 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 206010012735 Diarrhoea Diseases 0.000 description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
- 208000005189 Embolism Diseases 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 230000000890 antigenic effect Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 230000001900 immune effect Effects 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 208000005577 Gastroenteritis Diseases 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 229940124878 RotaTeq Drugs 0.000 description 7
- 230000002238 attenuated effect Effects 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 238000006386 neutralization reaction Methods 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 229940124941 Rotarix Drugs 0.000 description 6
- 229960001212 bacterial vaccine Drugs 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 210000003000 inclusion body Anatomy 0.000 description 6
- 229930027917 kanamycin Natural products 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 239000002122 magnetic nanoparticle Substances 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 229940009456 adriamycin Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000010102 embolization Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 4
- 241001478240 Coccus Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000606768 Haemophilus influenzae Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 229940031999 pneumococcal conjugate vaccine Drugs 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000001018 virulence Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000606790 Haemophilus Species 0.000 description 3
- 206010033078 Otitis media Diseases 0.000 description 3
- 208000035109 Pneumococcal Infections Diseases 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 206010067470 Rotavirus infection Diseases 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000000975 co-precipitation Methods 0.000 description 3
- 230000004154 complement system Effects 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 206010013023 diphtheria Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 229940031937 polysaccharide vaccine Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000000015 thermotherapy Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010061968 Gastric neoplasm Diseases 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 206010061190 Haemophilus infection Diseases 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 101710138767 Non-structural glycoprotein 4 Proteins 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 102100031056 Serine protease 57 Human genes 0.000 description 2
- 101710197596 Serine protease 57 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 238000005267 amalgamation Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000001727 anti-capsular Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 108700004675 bleomycetin Proteins 0.000 description 2
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000006392 deoxygenation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 208000006275 fascioliasis Diseases 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 229940029583 inactivated polio vaccine Drugs 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 150000002772 monosaccharides Chemical group 0.000 description 2
- 229940031346 monovalent vaccine Drugs 0.000 description 2
- 239000002539 nanocarrier Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 229940031767 13-valent pneumococcal conjugate vaccine Drugs 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 101710153593 Albumin A Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001614291 Anoplistes Species 0.000 description 1
- 241000432767 Asparagus setaceus Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 229940032024 DPT vaccine Drugs 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000702680 Equine rotavirus Species 0.000 description 1
- 241000242711 Fasciola hepatica Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017913 Gastroenteritis rotavirus Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 206010019635 Hepatic artery embolism Diseases 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- IGLKELDWPZFFKF-UHFFFAOYSA-N OC(C1=CC=CC=C1C(O)=O)=O.OC(C1=CC=CC=C1C(O)=O)=O.OC(C1=CC=CC=C1C(O)=O)=O.P.P Chemical compound OC(C1=CC=CC=C1C(O)=O)=O.OC(C1=CC=CC=C1C(O)=O)=O.OC(C1=CC=CC=C1C(O)=O)=O.P.P IGLKELDWPZFFKF-UHFFFAOYSA-N 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 229940124867 Poliovirus vaccine Drugs 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000702665 Porcine rotavirus Species 0.000 description 1
- 229940124950 Prevnar 13 Drugs 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 101710188053 Protein D Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101710138270 PspA protein Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 101710132893 Resolvase Proteins 0.000 description 1
- 241000702646 Rhesus rotavirus Species 0.000 description 1
- 229940124968 Rubella virus vaccine Drugs 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 241000710914 Totivirus Species 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 101150109847 VP8 gene Proteins 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002311 glutaric acids Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical class N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000027909 hemorrhagic diarrhea Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001027 hydrothermal synthesis Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011553 magnetic fluid Substances 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910001453 nickel ion Inorganic materials 0.000 description 1
- LGQLOGILCSXPEA-UHFFFAOYSA-L nickel sulfate Chemical compound [Ni+2].[O-]S([O-])(=O)=O LGQLOGILCSXPEA-UHFFFAOYSA-L 0.000 description 1
- 229910000363 nickel(II) sulfate Inorganic materials 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000007745 plasma electrolytic oxidation reaction Methods 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940021648 varicella vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Abstract
The invention discloses people's Rotavirus Vaccine, and it is the conjugate vaccines that multivalent pneumococcal polysaccharide forms with two or more carrier protein through connector, wherein, connector is that one of magnetic Nano microsphere, carrier protein is rotavirus protein.The preparation method of people's Rotavirus Vaccine forms multivalent pneumococcal polysaccharide with two kinds or more of carrier protein (one is rotavirus carrier protein) with magnetic Nano microsphere through coupling respectively.People provided by the invention is simple with Rotavirus Vaccine preparation technology, nanoparticle is used to strengthen mouse Th1 type immune responses for people's Rotavirus Vaccine of attachment, and immune lasting effect, specificity and the compatibility of polysaccharide specificity antibody, it additionally can induce mouse and produce rotavirus antibody;Possesses the preventive effect of two kinds of vaccines;Therefore there is very wide application prospect.
Description
Technical field
The present invention relates to a kind of vaccine, specifically, it is to be related to people with Rotavirus Vaccine vaccine and preparation method thereof, belongs to
Biological technical field.
Background technology
First, harm and counter-measure of the microorganism to human body
Microorganism typically refers to the biocenose that those body volume diameters are generally less than 1mm, and they are simple in construction, mostly
It is unicellular, going back some, even eucaryotic cell structure does not have yet, and microorganism is not present in we all the time at one's side, it will usually by
Microscope or electron microscope can just see their form and structure clearly;Wherein, pathogenic microorganisms be refer to cause the mankind,
The disease of animal and plant, there is pathogenic microorganism.A kind of pathogenic attack to host for depending on it of pathogen and
Host resistance is bred and resisted in vivo without the ability eliminated by it.Microorganism is pathogenic a generic character, and pathogenecity is strong
Weak degree is referred to as virulence.The establishment of infectious diseases not by the virulence unilateral decision of microorganism, will also regard the strong of host
Health situation and immune functional state.In general, the body that the strong microorganism infection of virulence be not immunized, can cause pathology to damage
There is apparent infection etc. in evil, and normal body can resist the infringement of many less toxic microorganisms (such as conditioned pathogen), but works as place
Main resistance then can be susceptible and pathogenic to these microorganisms when reducing.The virulence of pathogen and host resistance between the two compared with
Amount, the generation of infectious diseases is drawn, develops, lapse to and prognosis, because adaptedness is different between pathogen and host, both sides
The final result contended with is different, produces the different manifestations of a variety of patterns of infection, i.e. course of infection.It is pathogenic be to specific host and
Speech, some only have pathogenic to the mankind, and some is only to some animals, and some then category infecting both domestic animals and human microorganisms.And now place
Master is typically only possible by the infection that the immune system of itself carrys out combating microorganisms, and the death rate is very high, causes each researcher to grind
Study carefully vaccine and resist infringement of the invasive organism to human body.
And vaccine is divided into therapeutic and preventative two kinds, disease is treated by therapeutic vaccine, and passes through preventative epidemic disease
Seedling protects human body not encroached on by invasive organism.Come prevention disease it is the mankind in generation more than one by inoculating against property vaccine
In the clinical practice of discipline, it was demonstrated that be effective means.By effort for many years, medical field has been developed a variety of
Vaccine is to prevent, bacterium, virus and fungi etc., various diseases caused by infection, drastically increases the health of the mankind
It is horizontal.The continuous development of biotechnology, promote the variation of vaccine kind.Today, to infectious disease caused by pre- anti-virus
There are the vaccine that inactivation of viruses technological development comes out, such as Vaccinum Encephalitidis Epidemicae, polio vaccine, influenza vaccines;Use attenuated virus
Technological development come out attenuated live vaccine, as Rotavirus Vaccine, oral polio virus vaccine, measles virus vaccines,
Mumps virus vaccine, rubella virus vaccine and chicken pox vaccine etc..It is raw to prevent useful proteins and polysaccharide of bacterial infectious disease etc.
The technological development of thing macromolecule purifying come out bacterium class vaccine, as tetanus toxoid, diphtheria toxoid, DT-Pa and
Its subcellular components, epidemic meningitis Streptococcus polysaccharides and 23 valency pneumococal polysaccharides etc..With gene recombinant protein technological development
Vaccine out, such as hepatitis B surface antigen (prevention hepatitis B), human nipple shape viruslike particle virus (prevention cervix
Cancer) etc..The prevention meningitis and the bacterial vaccine of pneumonia developed with half chemical combination technology, such as popular haemophilus b
Type polysaccharide-protein combined vaccine, 7 valencys or 10 valency pneumococcal polysaccharide-protein combined vaccines and 4 valency meningococcal polysacharides-
Protein conjugate vaccines.As can be seen here, the development of medical biotechnology, it is the motive power that vaccine product continues to develop, by life
Thing technology is updated, and can develop more new generation vaccine products and human health is chosen to deal with different infectious diseases
War.
2nd, combined vaccine is summarized
Polysaccharide is a kind of important immune active ingredient in pathogen, have mycelial polysaccharides (OPS) and capsular polysaccharide (CPS) it
Point.After pathogen invades body, they can stimulate body to produce protective immune response as immunogene.But more sugars
Son belongs to the not dependent antigen of T cell (Ti-Ag), and less immunogenic, immune effect is especially undesirable after being inoculated with infant, and
Many harm serious disease meningitis, EColi O 157 as caused by haemophilus influenzae (Hib) at present:It is small caused by H7
Occurred frequently in the infant and clinical nothings such as youngster's hemorrhagic diarrhea dehydration effectively treat method, case fatality rate height (Wang Yan etc., with reference to epidemic disease
Seedling summarizes [J], microbiology immunology progress, 2000,28 (1):60-63).In order to improve the immunogenicity of polysaccharide vaccine, state
The chemical bond vaccine of polysaccharide and albumen, i.e. conjugate vaccines are risen at the beginning of 1920's outside, with reference to (using albumen as carrier
Bacterial polysaccharides class) polysaccharide covalent is incorporated on protein carrier and is prepared into polysaccharide-protein combination epidemic disease by vaccine using chemical method
Seedling, for improving the immunogenicity of bacterial vaccine polysaccharide antigen, such as b type haemophilus influenzaes combined vaccine, meningococcus knot
Vaccine and pneumococcal conjugated vaccine etc. are closed, short decades, its development was quite rapid, had obtained notable achievement.
3rd, the harm and its epidemiological study of pneumococcus
It is the main cause of whole world morbidity and mortality as the infection caused by pneumococcus (lung chain).Pneumonia, hair
Hot bacteremia and meningitis are the most common forms of expression of invasive pneumococcal disease, and the bacterium diffusion in respiratory tract
Middle ear infection, sinusitis or recurrent bronchitis can be caused.Compared with invasive disease, the form of expression of Noninvasive is generally not
It is so serious but more common.Due to the diffusion of antibiotics resistance sexually transmitted disease, and pneumococcal pneumonia is often in influenza infection
Occur afterwards, the possibility that pneumococcal disease breaks out during influenza further increases.
The disease triggered by streptococcus pneumonia has turned into a global important public health problem.Pneumococcus has turned into
The number one killer of global children.The case fatality rate of China's pneumonia is 16.4%, wherein more than 50 years old the elderly and less than 1 years old baby children
Youngster is up to 28.6% and 22.0% respectively.Carrying rate of China pneumococcus in healthy children is higher, and statistics are shown,
Carrying rate in northern area healthy children is 24.2%, southern area 31.3%.And the disease is to cause less than 5 years old children
Dead major reason.Main reason is that the development of infant immunisation system is not perfect, immunity is weaker.And the age gets over
Small baby, immunity are weaker.Pneumococcus about 90 kinds of serotypes (bacterial strain), the statistics in China show pneumococcus
Several serotypes are followed successively by before infection strain:5th, 6,19,23,14,2,4 type.860 plants of pneumococcus separation strains are have collected according to one
Studies have shown that there are 109 plants (12.7%) to show as sero-group 6, reached in the erythromycin resistance of Chinese Pneumococcus serotypes 6
100%, 6A, 6B and 6C type therein is respectively 62 plants (56.9%), 38 plants (34.9%) and 9 plants (8.2%).
Chemically in structure from the point of view of, above pathogen possesses a cell surface capsular polysaccharide (Capsular
Polysaccharide, CPS) or lipopolysaccharides (Lipopolysaccharide, LPS) shell, or both have concurrently, its function is side
Help pathogenic infection host.Capsular polysaccharide can shield bacterial cell surface functional component from being identified by host immune system,
Prevent complement system from being swallowed by bacterial surface protein activation and immunocyte, if bacterium is swallowed, capsular polysaccharide can prevent
Bacterium is killed.In most of pathogens, different bacterial strains expresses the capsular polysaccharide and lipopolysaccharides of different structure, and generation is a variety of not
Same serological type strain.Pneumonia and meningitis caused by pneumococcus are by a big chunk bacterium in known 90 kinds of serotype
Caused by strain infection.
As can be seen here, it is pathogenic to improve must to contain a variety of different types of bacterial polysaccharideses for most of bacterial polysaccharides class vaccines
Bacterial strain coverage rate, optimization and selection are an extremely complex epidemic disease in vaccine comprising which kind of bacterium or serotype polysaccharide
Knowledge is inscribed.Once specifying which kind of polysaccharide antibody has protective effect, then vaccine can be produced by the use of this polysaccharide as immunogene.
23 valency Pnu-Imune 23s of Chengdu Inst. of Biological Products of Chinese biological technology group production are to have chosen 23 kinds
Most common pathogenic bacteria (1,2,3,4,5,6B, 7F, 8,9N, 9V, 10A, 11A, 12F, 14,15B, 17F, 18C, 19A, 19F, 20,
22F, 23F, 33F), distinguish the various polysaccharide on fermented and cultured and separating-purifying pneumococcal capsule, be mixed by equal proportion
Vaccine.The polysaccharide of bacterium is a kind of thymus independent antigen, and the main distinction of this antigen and thymus dependent antigen is
The former does not need the auxiliary of T lymphocytes to produce antibody.Clinical practice proves that the vaccine that capsular polysaccharide makes is clearly effective,
And widely used in multiple countries.But there is problems with this kind of polysaccharide vaccine:(1) in brood or infants only
Faint immune response can be produced, does not produce immune response even, immune response strengthens with the growth at age;(2) produce low
The antibody of affinity;(3) of short duration immune response is only produced, does not possess immunological memory and Immune-enhancing effect effect during inoculation repeatedly
Should;(4) immune tolerance is easily produced;(5) common adjuvant is not easy to play a part of Immune-enhancing effect, 23 valency polysaccharide to this antigen
The protective rate that vaccine infects for intrusion type lung chain is 50-70%, and is only used for crowd's inoculation of more than 2 years old, and pneumonia
Peak age of onset be the 6-12 monthly ages;(6) polysaccharide with repetitive structure is the immunogene of the class of T cell self 2, without T
The participation of cell, they be can not inducing immunological memory effect, stimulate body caused by antibody be mainly IgM and IgG2, it is impossible to
Enough effectively activating complement systems.
The method of half chemical combination technology (also referred to as combination technology) vaccine development is the exploitation occurred from the 1980s
The technology of bacterial vaccine.John Robbins are by by popular influenzae type (Haemophilusinfluenzaetype
B, Hib) capsular polysaccharide (Polyribosylribitolphosphate, PRP), it is connected to protein carrier with the form of covalent bond
(tetanus toxoid) has synthesized popular influenzae type polysaccharide PRP- tetanus toxoid conjugates (PRP-TT),
After immune animal, the protection antibody of sterilization can be produced, so as to start bacterial vaccine development technique of new generation.Especially have
Meaning, for infant of the age less than 2 years old, due to developing immune system imperfection, polysaccharide is for infant
Belong to a kind of T-independent antigen, it is impossible to stimulate body to be produced adult and long-acting be directed to the polysaccharide
The bacterium specificity protection IgG antibody in source.Therefore, polysaccharide is a kind of haptens for the infant less than 2 years old, it is impossible to as
Vaccine is inoculated with the children less than 2 years old.When bacterial polysaccharides is connected into protein carrier in the form of covalent bond, such as tetanus poison
Plain (TetanusToxoid, TT), because protein is a kind of T cell dependence antigen, the polysaccharide of covalent key connection can be turned
Become T cell dependence antigen, the specific IgG antibodies of the polysaccharide are directed to so as to stimulate body to produce, protect body not
Infected by bacterium.The success of popular influenzae type polysaccharide-tetanus toxoid (PRP-TT) combined vaccine exploitation, is opened
The technology platform of an exploitation bacterial vaccine is created, i.e., by bacterial polysaccharides, such as capsular polysaccharide, O- specific polysaccharides (O-
Specificpolysaccharide) or oligosaccharide (Oligosaccharide), to be covalently bonded on protein carrier
Manufactured combined vaccine.Success based on this concept, medical biotechnology research circle open by using same chemical synthesis process
It has issued the combined vaccine of different bacterium;The combined vaccine of same bacterium is equally also developed with different synthetic technologys.
Capsular polysaccharide can shield bacterial cell surface functional component, make it from being identified by host immune system, prevent
Complement system is swallowed by the protein activation of bacterium surface and immunocyte.If bacterium is swallowed by immunocyte, capsular polysaccharide
Bacterium can be avoided to be killed.Capsular polysaccharide is one of major antigen composition of meninx Neisseria, as vaccine to larger
Children have certain protection.However, crowd of the capsular polysaccharide to 2 years old Infants Below, the elderly and B cell immune deficiency
Immune effect is poor, and Inoculant can not reach antibody level of protection, and antibody disappears quickly.The polysaccharide vaccine and other polysaccharide epidemic diseases
Seedling is the same, belongs to T cell independent antigen, has the immunogenicity that the age is related, and the reinforcement for not inducing T cell dependence should
Answer.By the way that polysaccharide conversion by polysaccharide and certain protein covalent bond, can be made into T cell dependence antigen, so as to stimulate baby young
The synthesis of the T cell dependence antibody of youngster, and booster response can be produced, while immunoglobulin (IgG) antibody can also be improved
Ratio.This polysaccharide conjugate vaccine can not only protect infant (less than 2 years old children), additionally it is possible to it is poor that resistance is significantly enhanced
Patient to the resistance of bacterium infection, therefore there is very wide application prospect.1980, JohnRobbins brominations
Cyanogen activates Hib capsular polysaccharides at random, then, regard adipyl dihydrazide (Adipic Dihydrazide, ADH) as attachment
(linker) it is added on the polysaccharide of activation, the polysaccharide covalent key after derivation is finally connected to the broken wound of carrier protein with EDC methods
On wind toxoid, popular influenzae type polysaccharide-tetanus toxoid conjugate (PRP-TT) is synthesized.Due to
There are multiple activation points on each polysaccharide chain, same on protein carrier there are multiple tie points, the conjugate of formation is a kind of polysaccharide
With the macromolecular of albumen interconnection, mean molecule quantity is about 5 × 106Da.1980, Harold Jennings were special in the U.S.
In profit 4356170, set forth with bovine serum albumin (Bovine serum albumin, BSA) is carrier, will be meningococcal
A, C group polysaccharide have synthesized epidemic meningitis polysaccharide-BAS and have combined epidemic disease by being connected on BSA with reducing amine method covalent bond
Seedling.1987 and nineteen ninety, PorterAnderson in United States Patent (USP) 4673574 and 4902506, are described with variation respectively
Avirulent strain diphtheria toxin 197 (Cross reactionmaterial sub197, CRM197) is used as carrier protein, to reduce amine
Method has synthesized popular influenzae type oligosaccharide-variation avirulent strain diphtheria toxin 197 (HbOC-CRM197) combined vaccine.Tool
The method of body is to use sodium periodate oxidation Hib capsular polysaccharides, produces the oligosaccharide for aldehyde radical in two ends, passes through reducing agent cyano group
Sodium borohydride (sodiumcyanoborohydride), oligosaccharide is covalently bonded on protein carrier.Form molecular weight about
For 90kDa lipopolysaccharides conjugate, it has been made containing the combination epidemic disease with 6 glycan molecules on 30% polysaccharide and each albumen
Seedling.Then, Merck (Merck, Sharpe and Dohme) is with mercapto chemistry, with the neisseria meningitis inflammation B of purifying
Group bacterial strain (Neisseria meningitidis groupsB) bacterial surface protein compound (outer membrane
Protein complex, OMP) protein carrier is used as, it is compound to synthesize popular influenzae type polysaccharide-bacterial surface protein
Thing (PRP-OMP) combined vaccine.With these synthetic technologys, three kinds of streams for being widely used in clinical inoculation are successively have developed
Row influenzae type combined vaccine, i.e. PRP-TT, PRP-HbOC and PRP-OMP.The success of Hib combined vaccines is to develop it
Its bacterium combined vaccine provides theory and technology basis, and subsequent exploitation enters the increasingly complex multivalence combined vaccine of technology
Stage, its reason are some infectious diseases, the pneumonia as caused by pneumococcus, meningitis caused by epidemic meningitis coccus etc.,
Can be caused by a variety of different serotypes or strain infection, and due to the chemistry of bacterial surface polysaccharides between each serotype or bacterial strain
The difference of structure, its antibody do not have cross-immune reaction, therefore, are inoculated with single serotype or bacterial strain combined vaccine, Wu Fabao
Shield is vaccinated infection of the human body from other serotypes or bacterial strain.For this reason, multivalence combined vaccine is synthesized and prepares to come
Expanding the protection coverage rate of vaccine turns into the main target of exploitation.
By effort for many years, the wide multivalence combined vaccine of a variety of coverage rates is have developed with combination technology.Bacterial capsule
Polysaccharide-protein combined vaccine appears in earliest in the 1930s, 3 type pneumococal polysaccharides are connected to by Goebel and Avery
On horse serum globulin, caused conjugate can produce the single-minded antibody of polysaccharide in animals, while provide corresponding immune
Protection.1987, first GL-PP combined vaccine, Type B haemophilus influenzae (HiB) polysaccharide-tetanus were malicious in the world
Plain (TT) combined vaccine is approved by the FDA in the United States into market.Merck & Co., Inc., Pfizer and Novartis Co., Ltd develop HiB in succession
Polysaccharide-tetanus toxoid conjugate and epidemic meningitis polysaccharide-tetanus toxoid conjugate, and successfully list.
2000, U.S. Hui Shi (Wyeth) company successfully developed and has listed 7 valency pneumococal polysaccharide-CRM197 combined vaccines, be by
7 different Pneumococcus serotypes polysaccharide are covalently bonded on CRM197 protein carriers respectively, mixed preparing form one
Kind polyvaccine, to prevent infantile pneumonia, it is popular that 7 Pneumococcal serotypes cover North America and Europe more than 90%
Pneumococcus different serotypes bacterial strain.2006, Sanofi Pasteur have developed 4 valency meningococcal polysacharides-broken wound
Wind toxoid combined vaccine, for preventing 4 kinds of epidemic meningitis coccus groups, i.e. A, C, Y, W135, caused meningitis.2009
Year, GlaxoSmithKline (GSK) have also been developed a kind of 10 valency pneumococcal polysaccharide-protein combined vaccines, to prevent
Pneumonia caused by 10 kinds of Pneumococcus serotypes.The vaccine has used three kinds of protein as protein carrier, wherein most main
The carrier wanted is albumen-D (Protein D, PD), and it is to be used as carrier by the use of this albumen to have 8 serotype polysaccharide.Albumen-D is to use
The gene recombination method of the popular haemophilus of non-separable express without esterification surface albumen, body can be stimulated to produce
Raw protection antibody, there is the otitis media acuta caused by the popular hemophilus infection for potentially preventing non-separable, and other are also
There are tetanus toxoid and diphtheria endotoxin to be used as carrier, be used separately as the egg of serotype 18C and 19F combined vaccine
Bai Zaiti.From the design above in association with vaccine product, it can be seen that the exploitation of combined vaccine is transitioned into technically from univalent vaccine
Increasingly complex polyvaccine, improve the coverage rate of bacterial vaccine.
GL-PP conjugate vaccines (combined vaccine) are current state-of-the-art vaccine technologies, and albumen is added on specific antigen
Matter carrier, its immunogenicity can be increased.Protein carrier has T cell dependency characteristic, and GL-PP conjugate vaccines can be thin by non-T
The polysaccharide antigen of born of the same parents' pauper character is changed into the antigen of T cell pauper character, and the t helper cell generation of excitating organism is a series of
Immune-enhancing effect.Capsular polysaccharide conjugate vaccine, protein carrier is added on polysaccharide, T cell is changed into from T-independent antigen
Dependence antigen, increase its immunogenicity.Caused antibody is generation vaccine in quality and quantity after combined vaccine inoculation
400-1000 times, generation immunoprotection is wider stronger, and guard time is more permanent, reaches efficient protection.2000, Pfizer was public
First 7 valent pneumococcal conjugate vaccines listing of department;Pfizer Inc. exploitation infant more targeted 7 (4,6B, 9V,
14th, 18C, 19F and 23F) valency pneumoprotein vaccine, it is also effective to less than 5 years old children.Capsular polysaccharide protein conjugate vaccines,
Add protein carrier on polysaccharide, T cell dependence antigen is changed into from T-independent antigen, its immunogenicity can be increased, can
For children more than 6 week old.At present Pfizer China registration 13 valency combined vaccines, add 6 serotypes (1,3,
5,7F, 6A, 19A).But the data in China shows that pneumococcal infection bacterial strain serotype is followed successively by:5、6、1、19、23、14、2、
4, the valent pneumococcal conjugate vaccine of Pfizer 7 only has 50% or so to China's common causative bacterial type coverage rate, and 13 valency combined vaccines
Coverage rate also only have 70%.The valent pneumococcal conjugate vaccines of Hui Shi 7 need to be inoculated with 4 injections, expensive per 860 yuan of pin, no
Beneficial to popularization.13 valency vaccines estimate that its price will be more expensive.Therefore the 7 and 13 valency combined vaccines of Pfizer Inc. are less suitable
Close the large-scale children Streptococcus prevention in China.
Although 13 valent pneumococcal conjugate vaccines have listed, wherein there is the immune effect of several serotypes with respect to it
His serotype is relatively low, such as 3 types.And with the increase of different serotypes and the reuse of carrier protein of the same race so that carrier egg
White dosage increases, and its immunogenicity reduces on the contrary.GlaxoSmithKline is developing 10 valency pneumococcal Polysaccharide Conjugate Vaccines
In design, have selected albumen-D is carrier, and its reason is the consideration based on two aspects.First, it is in order to avoid reusing
The tetanus toxoid and diphtheria toxoid as DPT vaccine component are as carrier.Clinical test shows, works as multivalence
Pneumonia combined vaccine contains with the univalent vaccine of protein carrier same composition or multiple vaccines while when being inoculated with other, such as
Hib-TT, whooping cough-Hib polysaccharide conjugate vaccines-IPV (inactivated polio vaccine)-hepatitis B vaccine (referred to as 6 vaccines),
The immunogenicity of most of serotype polysaccharide in multivalent pneumococcal combined vaccine can be suppressed, particularly to lockjaw
Toxoid influences to be especially apparent as the serotype polysaccharide immunogenic of carrier.Reason is made in multivalent pneumococcal combined vaccine
Tetanus toxoid and diphtheria toxoid total concentration for carrier is too high, is inoculated with the combined vaccine containing whooping cough component at the same time
When, such as 6 vaccines, so-called vector receptors Reverse transcriptase effect can be caused, reduces the immunogene of combined vaccine saccharide portion
Property.SanofiPasteur 11 valency pneumococal polysaccharide-TT and DT mixed carrier protein conjugate vaccines and Merck 7 valency pneumonia
Streptococcus polysaccharides-OMP combined vaccines (PCV-OMP), all it is that clinical test results are bad and cause the example of product development failure, it is former
Because just with this.Second, protein carrier is to confer to real protective immunity originality function.Clinical test proves albumen-D energy
Enough stimulate body to produce protection antibody, there is acute middle ear caused by potentially preventing non-separable popularity hemophilus infection
It is scorching.GlaxoSmithKline 10 valency pneumococcal Polysaccharide Conjugate Vaccines selection albumen-D is used as carrier so that protein carrier produces
Raw antibody has the protective effect of clinical meaning, is the much progress on combined vaccine technology development process.
But, the popular haemophilus actual clinical meaning of non-separable is by the low limit of the bacterial infection rate
System, the otitis media acuta incidence of disease caused by it infects are relatively low.It is exactly that albumen carries but these combined vaccines have a common ground shortcoming
Body does not assign the defencive function of immunogenicity, that is to say, that although combined vaccine carrier can stimulate body to produce antibody,
It is that the designer of vaccine does not have the protectiveness that has using its antibody to keep off infection, meanwhile, do not determine its generation yet
Antibody whether reach protectiveness titre levels.Tetanus toxoid, diphtheria toxoid and the nontoxic variant toxin of diphtheria etc. pass
System albumen the main reason for being selected as carrier, be not because their caused antibody has a protectiveness, but from its
Security and the immunogenicity of polysaccharide in conjugate can be strengthened to consider.It is clear that tetanus toxoid and diphtheria class poison
Element has been two components of PertussisDiphtheriaTetanus triple vaccine, by traditional vaccination;So tetanus toxoid in combined vaccine and white
Whether larynx toxoid carrier, which can stimulate body to produce, reaches that protection antibody titre is unimportant, opposite, in combined vaccine
The antibody titer of saccharide portion be only vaccine design person and need the subject matter paid close attention to.In addition, some knots just under development
Close the carrier used in vaccine product, the recombinant Pseudomonas aeruginosa exotoxin of the deletion mutant detoxification as expressed by E.coli
A (rEPA), the recombinant cholera toxin of the deletion mutant detoxification expressed by E.coli etc. is also all based on identical and considered.
The species and type of new polysaccharide conjugate vaccine are increasing year by year, and alternative carrier protein species is less, no
It is more that carrier protein is reused with vaccine.The different combined vaccines of inoculation same vehicle albumen may produce immunosupress effect
Should, cause influencing each other for immune effect between different vaccines.Moreover, main carriers albumen such as TT of polysaccharide conjugate etc., its
Itself is as vaccine ring vaccination infant, and original high titre specific antibody for carrier protein can in crowd's body
It can suppress specific immune response of the body to polysaccharide in combined vaccine.
Chinese patent (ZL02159032.X) discloses a kind of preparation method of polysaccharide-protein combined vaccine, and at present
Prepare one of most-often used technology of polysaccharide conjugate vaccine.In the technology, bridging agent is used as using adipic dihydrazide (ADH)
With reference to polysaccharide and albumen.This combination through cyanogen bromide-activated, i.e., uses cyanogen bromide in the basic conditions firstly the need of by polysaccharide
The hydroxyl acted on polysaccharide molecule, cyanate is formed, then reacted with ADH;A C―O bond cleavage in cyanate, with
Addition reaction occurs for the amino of ADH one end, so as to which ester hydrazides (AH) group is imported into polysaccharide molecule, forms polysaccharide-AH derivatives;
Polysaccharide-AH derivatives form stable conjugate under carbodiimide (EDAC) mediation with carrier protein.Such combination side
Formula can reduce the steric hindrance that polysaccharide is combined with carrier protein, remain the epitope of polysaccharide, while avoid polysaccharide in itself
Dissolubility, reduce the side effect of polysaccharide and antiserum reaction.
However, there is following weak point for above-mentioned traditional polysaccharide-protein combination technology:(1) polysaccharide-AH derivatives meeting
Continue to react with the polysaccharide of cyanogen bromide-activated, form the self-polymerization thing of polysaccharide, reduce the joint efficiency of polysaccharide-protein;(2)
EDAC easily causes the self-crosslinking of polysaccharide and carrier protein while mediating ADH derivation polysaccharide to be combined with carrier protein, from
And reduce the joint efficiency of polysaccharide-protein;(3) polysaccharide and carrier protein are macro-organism molecule, and only 6 carbon originals are leaned in centre
The ADH of sub- length is connected, and the structure of polysaccharide and protein will certainly influence each other so that the important epitope of some of polysaccharide is easy
Shielded by protein, and then reduce the immunogenicity of polysaccharide.Therefore, the immunogenicity and antibody of polysaccharide-protein combined vaccine
Lasting effect still needs further to be improved, and immune effect could be produced three times as polysaccharide conjugate vaccine needs to be immunized.These deficiencies
Place limits the further development of polysaccharide conjugate vaccine.
4th, the harm and its epidemiological study of human rotavirus
Worldwide, rotavirus (Rotavirus) is the main pathogens for causing children's seriousness to be suffered from diarrhoea, and is being sent out
Up to country, in the children being in hospital by acute diarrhea, the recall rate of rotavirus accounts for 35~52%.In the U.S., estimation has 300 every year
Ten thousand children suffer from rotavirus diarrhea, cause 82000 people's hospitalizations, 150 people death.In developing country, rotavirus is also
Cause 2 years old most common pathogen of Infants Below severe gastro-enteritis, the annual children for having more than less than 1.25 hundred million 5 years old of estimation suffer from
Diarrhea Caused by Porcine rotavirus, wherein 1,008,000,000 children suffer from mild diarrhea, 870,000 is dead.In China, Child birth rat about 1,000
7000000, estimate that annual about 350,000 children cause death due to suffering from rotavirus diarrhea, arrange second place of the world.Due to described
The increase of the incidence of disease and fatal rate that the infection of virus was suffered from diarrhoea to 2 years old Infants Below has remarkable effect, exploitation prevention colyliform disease
Poison infection, effective and safe vaccine is the task of top priority.
Rotavirus Reoviridae (Reoviridae genus), is the disease for causing the mankind and numerous animal diarrheas
Substance.Totivirus diameter 70nm, there are three special shell structures, the core shell structure of innermost layer is nucleocapsid protein, is enclosed with virus
Gene.The gene of virus is made up of 11 segmented fragments of AMPLIGEN, is that 6 structural proteins and 5 non-structural proteins are compiled
Code.Nucleocapsid protein is made up of tri- virus proteins of VP1, VP2 and VP3;Middle glutelin is VP6, coat protein be by VP4 and
VP7 is formed.Because the gene of rotavirus is bifilar RNA, multi-disc segment structure, the gene of this structure can be carried out between gene
Reconfiguring to a certain degree, i.e. rotavirus gene matches somebody with somebody (reassortment) again.When two or multiple viruses are same
When infect a host cell after, in the packing stage of reovirion, each viral genetic fragment will in the cell again
Combination, causes to match somebody with somebody gene again.This heavy ability with gene of rotavirus result in human body to the various of its immune response
Property, also increase the difficulty for making specific Rotavirus Vaccine.
Rotavirus is divided into different types, hypotype and serotype according to the difference of virus antigenicity.7 are had now found that
Serotype (A types~G types), most of human pathogens belong to A, B and c-type.Epidemiology survey finds to cause human and animal
It is most common with A types in ill rotavirus, it is the main target of vaccine development.A types rotavirus is according to its VP6 antigenic characteristic
Difference, be categorized further, as hypotype, one kind that most Strain belong in hypotype I or II.Different rotavirus tables
Face-piece albumen VP7 and VP4 neutralization epitope cluster are different, can independently induce respective neutrality antibody, viral blood
Clear type can be determined by the specificity of VP4 and VP7 antigens.A types rotavirus can be further categorized into according to VP7 and VP4 difference
G serotypes and P serotypes.Because rotavirus gene is made up of 11 fragments, VP7 and VP4 encoding gene can be independent
Separation combination, generate the gene resortment that a kind of binary mode is carried out.VP7 is a kind of glycoprotein (glycoprotein), because
Its antigenic characteristic is divided into 15 kinds of different G serotypes, relative with its specific nucleotide sequence, i.e. genotype (genotype)
Should;That is, every G serotypes have its special genotype, therefore, usual G serotypes and G genotype are generally applicable.Entirely
In human disease's rotavirus strain that ball identifies, what it is more than 90% is G1, G2, G3, G4, and G9 strain, shares 10 serotypes
Separated from human body and (be shown in Table 1).VP4 is a kind of two different virus proteins, i.e. VP8 can be cut into by trypsase
It is P serotypes by its antigenic serotypes that are different and determining, some P serotypes can further divide with VP5 virus proteins
For 2 sub- serotypes.The serum or monoclonal antibody of different VP4 Serotypes are distinguished due to lacking, hinders VP4 serum
Type parting.RT-PCR application just makes it possible VP4 genotyping, and applies to the epidemiology survey of sample.
Therefore, VP4 is substantially classified according to gene order, finds 14 P serotypes and at least 26 P genotype altogether at present
(being marked in bracket).P serotypes and P genotype may not be corresponded to, it is necessary to mark, for example, Rotavirus Wa strain strain is marked simultaneously
It is shown as P1A [8] G1 viruses.In the strain of human disease, G1, G3, G4 and G9 P and G serotypes combination are typically P1A [8], and
G2 is typically P1B [4].As can be seen here, worldwide the rotavirus of prevalence enjoys the epitope cluster of identical cross-neutralization
(epitopes) P1 serotypes, at least 7 VP4 serotypes are found in human rotavirus.On epidemiology intentionally
The G serotypes 1 of mankind's strain of justice, 3, and 4 be the 1A Asias serotype for belonging to P serotypes, and G serotypes 2 are the 1B of P serotypes
Sub- serotype.
Because natural rotavirus infection can induce immunoprotection, at least infection to severe rotavirus well,
Therefore, the effort of most of vaccine developments is placed on attenuated live vaccine.Initial research, which concentrates on, uses animal rotavirus strain,
Carried out by being referred to as Jennerian methods, reason is that the animal strain of nature attenuation in human body is safe, and is mainly produced
Raw is mixed type immunoprotection.
After finding that rotavirus is the pathogen 10 years for causing children's seriousness to be suffered from diarrhoea, in nineteen eighty-three, start to use pig
Rotavirus strain RIT4237 (G6P [1] type), manufactured first rotavirus attenuated live vaccine has carried out clinical test, in sweet smell
The result of orchid experiment shows that the vaccine is safely effectively, to pass through mixed type human rotavirus
The effect of (heterotypichuman rotaviruses), the protective rate of prevention severe rotavirus diarrhoea is up to 80%.But
Disappointing in the clinical trial result that subsequent other countries are carried out, display is low or without protective effect, the experiment with
End up in failure.In 1987, monkey rotavirus RRV strains were used to develop attenuated live vaccine, were the rotavirus of first exploitation
Another in vaccine.Clinical test shows, although the vaccine can induce body to produce protection antibody, result is unstable
It is fixed, trace it to its cause and be, the G serotypes of RRV strains are G3P [3], when the rotavirus of human infection is the G serotypes of homotype
When, i.e. G3, the significant effect of vaccine;If during the G serotypes infection of different shaped, then it is ineffective.Then, RRV strains pass through
VP7 genes in mankind's strain are incorporated into the strain by the method for gene resortment so that common in human rotavirus
Other three kinds of G serotypes G1, G2 and G4 can also be expressed on RRV recombined strains, and which results in 4 valency Rotashield vaccines
Succeed in developing.The vaccine obtained FDA approval list marketings in 1998, but due to being found that minority after large-scale inoculation,
But the generation of the significantly raised entembole side effect case of quantity, in 1999 by production company under city.In 1988, open
Begin use another rotavirus strain, i.e. WC3 pigs strain (G6P [5] type), carry out clinical test when, start result prove effectively,
But significant protectiveness is displayed without in a subsequent experiment, the vaccine, which also stopped, to be continued to test.To nineteen ninety, in order to
So that the antigenic structure of WC3 strains passes through gene resortment (gene reassortment) side closer to human rotavirus
Method, it will be incorporated into for the gene of VP4 and VP7 encoding histones from human rotavirus on WC3 recombined strains, this method is referred to as
For improved Jennerian methods.The strain and method are exactly developing RotaTeq 5 valencys by Merck
(pentavalent) development approach of vaccine.2006, the WC3- gene resortment vaccines RotaTeq of 5 valencys is produced by Merck
Go through to list, the vaccine contains the two human rotavirus's albumen substituents of VP7 and VP4 because of i.e. G1, G2, in G3, G4
Corresponding VP7 GFPs, and P [8] corresponding VP4.Clinical test shows that the vaccine does not have entembole side effect,
It is 74% to the protective rate of the gastroenteritis caused by G1-G4 rotavirus, to the protective rate of severe gastro-enteritis up to 98%, to living
The protective rate that institute and acute disease access is 94.5%.The same year, human rotavirus's attenuated live vaccine Rotarix of GSK productions are also obtained
Approval must be listed, this vaccine is the mankind strain 89-12 based on attenuation, and serotype is G1P [8] strain, be in world wide most
Common serotype.The virus is separated from the patient clinical samples for suffering from rotavirus gastroenteritis, and is being organized
Cell obtains after repeatedly passing on variation attenuation.Clinical test shows, after two dosage are injected, to all rotavirus infections
Protective rate to the protective rate of serious gastroenteritis up to 96%, is reached to the protective rate for needing gastroenteritis case in hospital up to more than 87%
100%.Further experiment shows, the scope protection of the vaccine not only includes the gastroenteritis as caused by G1P [8] strain, and
Include the G3P relevant with VP4 [8], gastroenteritis caused by G4 [8] and G9P [8] strain.To G3, G4 and G9 rotavirus infections are protected
The validity of shield is identical with G1's, has exceeded 95%, and the validity to G2 strains is 75%, and gastroenteritis is caused to all rotavirus
Protective rate in hospital is 75%.
Statistics shows that G1 strains are worldwide most commonly detected strains, in Asia, North America and Europe, G1-
G4 strains account for the 97.5% of total infection rotavirus.In South America, Africa, Australia account for 83.5%-90.4%, meanwhile, at this
A little regional G5, G8 and G9 strains start to become important.From the point of view of P serotypes, P1A [8] strain is most common, ensuing to be
P1B [4] strain.This result is predictable, is most commonly detected VP7 serum because VP7 serotypes G1 is P1A [8]
Type;The important VP7 serotypes of other two epidemiology, G3 and G4, it may have identical VP4 serotypes.Another main blood
Clear type G2 VP4 has the feature of P1B [4].Although G and P serotypes or genotype can have a variety of different combinations, 4 kinds of P-
G combination, i.e. P [8] G1, P [4] G2, P [8] G3, and P [8] G4 constitute 88.5% common pathogenic strain.
As can be seen here, if configuring vaccine, it is necessary to comprising a variety of different G serotypes poison with the VP7 albumen of G serotypes
Strain improves the coverage rate of vaccine, i.e. G1, G2, G3, G4, G9, G8 and G5, and the rotavirus attenuated live vaccine of 7 valencys is also current
Develop the striving direction of vaccine of new generation.If developing Rotavirus Vaccine from another strategy, albumen is determined with P serotypes
VP4 difference can then greatly reduce the strain kind included in vaccine and be covered to reach identical hair to prepare the vaccine of a new generation
Rate.Analysis more than, if preparing vaccine with P [8] and P [4] two P serotypes strains, immune effect will be with 7
The G serotypes of valency are suitable.From the point of view of Rotarix the and Rotateq effects clinically used, almost it is not different, moreover, existing
Statistics on see, Rotarix seems more more effective than Rotateq.From analyzing the strain serotype that is included of the two vaccines
From the point of view of the composition for determining albumen, Rotarix is only containing a kind of this VP7 virus protein of G1;Although Rotateq contain G1, G2, G3,
With G4 four kinds of VP7 virus proteins, immune effect does not strengthen;And the P serotypes contained from both determine albumen VP4 number
From the point of view of amount, Rotarix contains P [8] one kind, and Rotateq contains P [8] (one of strain) and P [5] (the original strains of WC-3
For G6P [5]) two kinds;But the content of the important antigenic component P [8] in Rotarix will be above the content in Rotateq.Thus
It can be seen that being assessed from the angle of P serotypes, the VP4 strain Rotavirus Vaccines containing P [8] have great meaning.If new one
For P [8], the P [4] and [6] three kinds of VP4 antigenic components of P for including P serotypes in vaccine, you can cover global most area
Popular strain.
5th, application and prospect of the nanoparticle in biotechnology
Nano material refers to that crystallite dimension is less than 100 nanometers of monocrystal or polycrystal, unique small-size effect and table
The effect such as face or interface, makes it possess many excellent or brand-new performance, and it is just being increasingly subject to the attention of people.Such as receive
Continuous infiltration and influence of the rice material on drug research field, have triggered the remote revolution of the field depth of drug field one.Medicine is
The mankind be used for resist with prophylactic important substance, for a long time, the research and development of medicine provide many for clinic
Treatment means, bring many benefits for patient.But there are still many problems, such as medicine to follow for existing medicine
Be detained in loop system and reach valid density, specific therapeutic purpose can not be reached, can not by blood-brain barrier, can not be at some
It is partially formed higher concentration and does not produce (application of Wu Xin honor drug-carried nanometers and the progress such as toxic side effect simultaneously
[J] Chinese Hospitals materia medica magazines, 2001,21 (3):171-173.).Magnetic Nano microsphere pharmaceutical carrier be nanometer technology with
The product that modern medicine and pharmacology combines, because it has small-size effect, good targeting, biocompatibility, biological degradability
And the advantages that functional group, therefore be expected to overcome these defects caused by conventional medicament.Magnetic nanometer particles can also be used for egg
Purifying, recovery and the enzyme immobilizatio of white matter and enzyme, it is simple to operate, and improve the stability of enzyme.Utilize magnetic nanometer particles
Immunoassay is carried out, there is the characteristics of specificity is good, separation is fast, favorable reproducibility.PCI is carried out using Magnetic Microspheres-Carrier,
In the intravascular carry out embolism of magnetic control, then there is magnetic control guiding, target position embolism.
Application of the magnetic Nano microsphere in biomedicine specifically has with the deeply increasingly extensive of research:
1st, immobilised enzymes
Boiomacromolecule all has many functional groups such as enzyme molecule, can pass through physical absorption, crosslinking, covalent coupling
They are fixed on to the surface of magnetic particle etc. mode.It is with the advantages of magnetic Nano microsphere immobilised enzymes:It is easy to enzyme and bottom
Thing and product separation;Improve the biocompatibility and immunocompetence of enzyme;The stability of enzyme is improved, and simple to operate is reduced into
This.Bendkiene etc. is prepared for chitosan magnetic microsphere, as fixation support., can after enzyme is fixed on this carrier
Easily to be separated and recovered with magnetic devices from the mixed liquor of reaction.Domestic researcher also explores to this respect,
Ding little Bin etc. uses dispersion copolymerization method, synthesizes Fe3O4/ (St-MPEO) (St- styrene, MPEO- PEOs polymeric monomer)
Microballoon, the microballoon have amphiphilic structure, all have good swelling behavior in most of polarity, apolar medium so that
The immobilized compound of microballoon all has higher activity (Ding XB, Wei L, Zhao HZ.Synthesis in a variety of media
and characterization of aliphatic polycarbonatediols[J].Applied Polymer
Science, 2001,79 (3):1847-1851).The magnetic Nano microsphere carrier is expected the purifying for protein and enzyme, returned
The field such as receipts and enzyme immobilizatio, cell separation.
2nd, targeted drug
Medicament carrier microspheres with targeting refer to that drug bearing microsphere can highly selectively be distributed in effective object, so as to strengthen
Curative effect, reduce side effect.Initial target medicine carrier microballoon be according to clinical needs, by from it is various to body tissue or
The different carrier of diseased region affinity makes drug bearing microsphere, or monoclonal antibody is combined with carrier, defeated to allow medicament to
It is sent to the privileged site that treatment it is expected to reach.With requirement more and more higher of the people to treatment, targeting positioning is also because by matrix
Limit and be not entirely satisfactory, therefore there have been magnetic Nano microsphere drug-loading system.This system is in externally-applied magnetic field
Under effect, people is noted to pathological tissues by dynamic (quiet) arteries and veins, carrier is directed to diseased region (target position), is determined contained drug
Position release, focuses on diseased region and has an effect (A Paul, Alivisatos.Ultrasensitive magnetic
Biosensor for homogeneous immunoassay [J] .Science, 2001,12 (5):53-60).Germany
Lubbe etc. completes the clinical trial of first case applied magnetic drug targeting treatment in the world.Suffer to 14 advanced solid tumors
In the magnetic target therapy of person, it is found that patient is fine to the tolerance of magnetic targeted drug.Lexion etc. also make by applied magnetic microballoon
Squamous carcinoma (Lexion C, Amold W, Klein RJ, the et al.Locotegional cancer of rabbit are treated for pharmaceutical carrier
Treatment with magnetic drugtargeting [J] .CancerRes, 2000,60 (23):6641-6648), state
Interior Tao Kaixiong etc. with adriamycin magnetic albumin microspheres treat mouse implanted gastric tumor (Tao Kaixiong, Sun Hongwu, Chen Daoda, wait Ah
Mycin Magnetic albumin microsphcres targeted therapy mouse implanted gastric tumor [J] China experimental surgery magazine, 2000,17 (1):63-
64)), the bleomycin A5 magnetic microsphere treatment oral cavity top collar portion cvernous hemangioma 25 such as Guo Jun.In addition, high-intensity magnetic field also has
Cancer suppressing action (Guo Jun, Li Cheng, Wu Hanjiang bleomycin A5 magnetic microsphere targeted therapy oromaxillo-facial regions cvernous hemangioma 25
Clinical report [J] Nanjing Railway College of Medicine journal, 2000,19 (2):112-114)).The glucose magnetic microsphere such as Xu Huixian
Immobilization L- asparagus ferns phthalein amine enzyme treats acute lymphatic leukaemia, also achieves good therapeutic effect.These results all show,
Increase with the magnetic and medicated aggregation in tumor locus of raising of magnetic field intensity, acted on using the magnetic steering of externally-applied magnetic field, make medicine
Pinpoint in target site, play concentration, efficient antitumor action.Targeting and surface just because of magnetic Nano microsphere combine
Idiosyncratic carrier, make people be expected to be utilized to follow the trail of and eliminate the cancer cell that is shifting, so as to be eliminated as in human body
" biological missile " of cancer cell.But the tumour of applied magnetic drug therapy is much nearer positioned at body surface or in vitro table at present, therefore
The intensity of externally-applied magnetic field can be weaker, and easily controllable, if the tumour for the treatment of deep organ or tissue, needs to be optimized
Magnetic field intensity, positioning and Pharmaceutical carrier particles size etc..And the intensity of magnetization that improve magnetic microsphere then has certain difficulty, because
Its magnetic property can be substantially reduced for the clad on magnetic particle surface, in addition, the controllable of granular size is also to have to be solved one
Individual problem.
3rd, cell separation and immunoassay
If magnetic particle surface, which is drawn, connects the specific antibodies with bioactivity, in the presence of externally-applied magnetic field, utilize
The specific binding of antibody and cell, it is possible to obtain immune magnetic microsphere (Immunomagnetic microspheres,
IMMS) or immune magnetic pearl (Immunomagnetic beads, IMBS), using they can fast and effeciently by cell separation or
Carry out immunoassay.When being separated in particular by IMBS to antigenic substance specific to cell, organelle surface, there is letter
Just quick, separation purity height, the features such as target substance activity is retained.The adult that Mccole etc. was infected with IMBS separation by liver fluke
T lymphocytes in ox peripheral blood, the cell separated is pure, is worked well for liver fluke infection mechanism.John is with being connected with list
Anti- IMMS detections salmonella, whole detection process only need 2-3h, and sensitivity be 103-104 thalline/ml, a certain amount of blood with
The presence of excrement is noiseless to analyzing, and compared with agglutination and immunofluorescence technique, sensitivity improves 103 times.Glenn is with IMBS points
Inclusion virus is closed from breathing, with reference to ELISA, the diffusion reduced in conventional tube and micropore analysis is inhaled with non-specific
Attached, the formation of compound only needs 7min, and conventional microporous rule needs 120min.The isolation technics of cell can be additionally used in controlling for cancer
Treat.The superfine covalently bound methods of physical absorption combination chemical bond of Kang Ji, anti-human wing moon bright carcinoma monoclonal antibody are connected to pre-
The surface of the Magnetic Polystyrene Microsphere carrier first prepared, constructing can specifically be combined with target cell and assign it with magnetic response
The immune magnetic microsphere of property.As a result show, constructed IMMS can be combined effectively with target cell, with IMMS from marrow
The preliminary experiment of separation cancer cell shows that IMM can effectively remove cancer cell, and bone marrow cell only has minimal amount of loss.It is immune
Analysis in modern biotechnology analytical technology is a kind of important method, its quantitative analysis to protein, antigen, antibody and cell
Play huge effect.Immunoassay is carried out using the carrier-bound antigen of magnetic nanometer particles or antibody, there is specificity
High, the features such as separation is fast, favorable reproducibility.Jing Xiaoyan etc. uses agalactosis polymerization, in the aqueous systems of alcohol one, using potassium persulfate as
Initiator, initiation point is formed in Fe3O4 magnetic fluids particle surface, with acrylic acid (AA) for stabilizer, is passed through styrene (ST)
With propylene phthalein amine copolymer, prepare monodispersed amido magnetic microsphere, the microballoon can directly, quickly with antibody (antigen) albumen
Matter is crosslinked, and the shortcomings that protein is crosslinking agent (Jing Xiaoyan, king need to be used when avoiding other functional group microballoon combination immunoreagents
Monarch, Li Rumin, wait preparation research [J] applicating technologies of magnetic function polymer microspheres, 2000,27 (1):16-17)).
4th, magnetic control inspection plug
During common people Jie treats, it may occur that phenomena such as dystopy embolism and infarct, and cause serious complication,
This is the thorny problem for being clinically badly in need of solving, and uses people Jie of Magnetic Microspheres-Carrier to treat, in the intravascular carry out bolt of magnetic control
Plug then has the advantages that magnetic control guiding, target position embolism, and approach is provided to solve above problem.Scholars focus on magnetic spherolite
Footpath, magnetic control time, magnetic field intensity, magnetic microsphere lapping (coarse, carrying positive charge, having hydrophobic property) etc. are done
Careful research.The therapy that Minalnimura etc. is combined with thermotherapy and arterial embolism is used for the research of mouse liver cancer model.He
Have developed DM-MS arterial ducts locally be administered, additional 500kHz magnetic field.After treating 3d, tumour growth rate (embolism-thermotherapy
Group, simple embolization group and control group) be respectively 28%, 124% and 385% (Minalnimura T, Sato H, Kasaoka S,
et a1.Tumor regression by inductive hyperthermia combined with hepatic
embolization using dextran magnetite incorporated microspheres in rats[J].Int
J Oncol, 2000,16 (6):1153-1160).It is a kind of antitumor that this research display DM-MS thermotherapy and embolism, which are combined therapy,
Feasible sex therapy, there is wide research and application prospect.Goodwin etc. is to adriamycin magnetic microsphere hepatic artery embolism and medicine
Target and (Goodwin SC, Bittner CA, Peterson CL, et are studied to the toxicity of antitumor therapy
al.Single-dose toxicity study ofhepatic intra-arterial infusion ofdoxorubicin
Coupled to a novel magnetically targeted drug carrier [J] .Toxical, 2001,60 (1):
117-183).The pork liver cancer model result that they establish shows that adriamycin magnetic microsphere low dosage has no toxic side effect.Only work as magnetic
Just there are preferable effect, the degree of necrosis and bolt of liver cancer cells in content >=75mg (with or without adriamycin) target area of property microballoon
Plug degree is directly proportional, and adriamycin can not freely circulate in whole body and successfully be controlled in target area.Hui Xuhui etc. is gathered with homemade
Methyl methacrylate vinegar magnetic microsphere is inquired into Endovascular Embolization, and experiment shows, 30-50um PMMA magnetic microspheres tool
Have the advantages that magnetic response ability is strong, magnetic control embolization effect is good, remain to realize target position embolism in the case of high Hemodynamic environment, be it is a kind of compared with
Good magnetic control Endovascular Embolization material (Hui Xuhui, Gao Lida, polymethyl methacrylate magnetic microsphere vascular peg stays before what energy
Fill in experimental study [J] Sichuan medical science, 2001,22 (10):928-929)).In magnetic control embolism, the size of Magnetic Microspheres-Carrier
It is to influence the most important factor of Target localization.If particle diameter is smaller, magnetic responsiveness is weak, and magnetic control degree is poor, it is impossible to be used in high blood
Flow velocity or compared with the endovascular magnetic control embolism of Large Diameter Pipeline.Therefore, the application with magnetic microsphere in other respects is different, in magnetic control
In embolism people Jie treatment, the general magnetic microsphere larger using particle diameter.
Also report points out, nanoparticle can be as the carrier protein and adjuvant of DNA vaccination, but is applied to preventative polysaccharide
And/or protide vaccine has no report.
The content of the invention
In view of the above-mentioned problems existing in the prior art, it is an object of the invention to provide a kind of stronger people's wheel of immunogenicity
Shape viral vaccine.
For achieving the above object, the technical solution adopted by the present invention is as follows:
People's Rotavirus Vaccine, it is for multivalent pneumococcal polysaccharide with two or more carrier protein through being connected
The conjugate vaccines that body forms, wherein, connector is that one of magnetic Nano microsphere, carrier protein is rotavirus protein.
As a kind of preferred scheme, the inside that the magnetic particle of the magnetic Nano microsphere is located at magnetic Nano microsphere is
Core, high polymer material are wrapped in the outside of magnetic particle.
As further preferred scheme, magnetic particle Fe3O4。
As further preferred scheme, magnetic Nano microsphere particle diameter is 0.1-10 μm, preferably 0.1-5 μm.
As another preferred scheme, high polymer material is bioabsorbable polymer material, selected from chitosan, polyethylene glycol, is gathered
One or more of mixtures in poly lactic coglycolic acid (PLGA), PLA-PEG copolymer (PELA);
Most preferably PLGA or PELA.
As another preferred scheme, multivalent pneumococcal polysaccharide is a variety of pneumococcal capsular polysaccharides, is preferably separated
Purify the capsular polysaccharide on Pneumococcal serotype pod membrane, the serotype of the Pneumococcal serotype includes 1,2,3,4,5,
6A, 6B, 7F, 8,9N, 9V, 10A, 11A, 12F, 14,15B, 17F, 18C, 19A, 19F, 20,22F, 23F and/or 33F.
As further preferred scheme, the mass ratio of multivalent pneumococcal polysaccharide and two kinds of carrier proteins is (0.5~2):
1, be preferably (0.5~1): 1, wherein the mass ratio between each carrier protein is preferably 1: 1.
As further preferred scheme, the rotavirus protein is restructuring human rotavirus albumen.
As a kind of preferred preferred scheme, the carrier protein is selected from diphtheria toxoid, tetanus toxoid, carrier protein
CRM197, bloodthirsty Bacillus influenzae surface protein HiD, pertussis Pm surface proteins, pertussis Fha antigens and/or pneumococcus table
Face albumin A (rPspA).
As further preferred scheme, it is bloodthirsty Bacillus influenzae surface protein HiD or lung to have one kind in the carrier protein
Scorching coccus surface protein A (rPspA).
As further preferred scheme, recombined human rotavirus protein is the part amino of P genotype rotavirus proteins
One kind in acid sequence or complete sequence, preferably P genotype rotavirus strain P [8], P [4], P [6] or P [11];Wherein, P
Genotype rotavirus strain is selected from one in P [8] G1, P [4] G2, P [8] G3, P [8] G4, P [8] G9, P [8] G5 or P [6] G8
Kind.
As still more preferably scheme, P genotype P [8] rotavirus strain be selected from Wa, Ku, P, YO, MO, VA70,
D, AU32, CH-32, CH-55, CHW2, CH927A, W161, F45, Ai-75, Hochi, Hosokawa, BR1054, WT78 or
One kind in WI79 strains.
As still more preferably scheme, P genotype P [4] rotavirus strain be selected from DS-1, RV-5, S2, L26,
One kind in KUN, E210, CHW17, AU64,107E18, MW333 or TB-Chen strain.
As still more preferably scheme, P genotype P [6] rotavirus strain be selected from M37,1076, RV-3, ST3,
One kind in SC2, BrB, McN13, US1205, MW023, US585 or AU19 strain.
As another further preferred scheme, recombined human rotavirus protein be selected from VP8, VP4, VP8 polypeptide chain fragment,
One kind in core VP8, VP4 polypeptide chain fragment, VP8 specific antigen cluster peptide chains or VP4 specific antigen cluster peptide chains.
As another further preferred scheme, recombinant rotavirus albumen is the VP7 albumen of G serotype rotavirus
Partial amino-acid series or complete sequence.
As another further preferred scheme, recombinant rotavirus albumen is the VP7 albumen of G serotype rotavirus
Partial amino-acid series or complete sequence.
As still more preferably scheme, G serotypes rotavirus strain is selected from G1, G2, G3, G4, G9, G5, G8, G10
Or one kind in G11 serotypes.
As still more preferably scheme, the G serotypes rotavirus strain be selected from P [8] G1, P [4] G2, P [8] G3,
One kind in P [8] G4, P [8] G9, P [8] G5 or P [6] G8 serotypes.
It is a further object of the present invention to provide the preparation method of people's Rotavirus Vaccine, specifically by multivalence pneumonia ball
Granulose forms with two kinds or more of carrier protein through coupling.
As a kind of preferred scheme, the preparation method of the conjugate vaccines, following steps are specifically included:
A) capsular polysaccharide on difference separating-purifying various serotype pneumococcal capsule;
B) carrier protein simultaneously selected by separating-purifying is prepared respectively;
C) various capsular polysaccharides and magnetic Nano microsphere are coupled into polysaccharide-magnetic Nano microsphere couplet respectively;
D) polysaccharide-magnetic Nano microsphere couplet is combined with variety carrier albumen coupling respectively again;
E) couplet obtained by purification procedures d) is into the conjugate vaccines stoste.
As further preferred scheme, the preparation method of the conjugate vaccines, following steps are specifically included:
A) capsular polysaccharide on difference separating-purifying various serotype pneumococcal capsule;
B) the variety carrier albumen selected by difference separating-purifying;
C) various capsular polysaccharides and magnetic Nano microsphere are coupled into polysaccharide-magnetic Nano microsphere couplet respectively, then passed through
Chemical modification, so as to which-OH of the polysaccharide-magnetic Nano microsphere couplet surface not with polysaccharide reaction is modified as into-CHO;
D) polysaccharide-magnetic Nano microsphere couplet is combined with variety carrier albumen coupling respectively again;
E) couplet obtained by purification procedures d) is into the conjugate vaccines stoste.
As further preferred scheme, the preparation method also includes preparing magnetic Nano microsphere, including first prepares nanometer
Magnetic particle prepares the process of magnetic Nano microsphere again;Wherein magnetic nanoparticle can by chemical coprecipitation, hydro-thermal method or
Prepared by sol method pyrolysismethod, magnetic Nano microsphere can be prepared by investment, monomer polymerization method or in-situ method, preferably useization
Learn coprecipitation and prepare magnetic nanoparticle and again emulsify magnetic nanoparticle and high polymer material through fast film and extract with reference to solvent
Follow the example of and/or investment or monomer polymerization method prepare magnetic Nano microsphere;Nanometer is most preferably prepared using chemical coprecipitation
Magnetic particle is again prepared magnetic nanoparticle and high polymer material through fast film emulsification with reference to solvent extraction and/or investment
The magnetic Nano microsphere of uniform particle diameter;Wherein magnetic particle is preferably Fe3O4。
As still more preferably scheme, the preparation method of above-mentioned nano-magnetic ion can refer to Fe in the prior art3O4
Prepared by the method for magnetic Nano microsphere, for details, reference can be made to following embodiments, whether achievable is not intended as the present invention
Key factor.
As still more preferably scheme, the separation purifying technique of polysaccharide can be according to required polysaccharide and albumen in step a
Species is operated according to prior art.
As still more preferably scheme, the preparation of the albumen in step b and separation purifying technique can be according to required more
Sugar and protein classes are operated according to prior art.
As still more preferably scheme, step c concrete operations are:In coupling medium reaction buffer, at room temperature,
Under pH4.0-9.0, polysaccharide obtained by step a and magnetic Nano microsphere coreaction 6-24 hours are obtained into polysaccharide-magnetic Nano microsphere idol
It is conjuncted, then it is further modified by 25% glutaraldehyde so that polysaccharide-magnetic Nano microsphere couplet surface not with it is more
- the OH of sugar reaction is modified as-CHO;Wherein coupling medium is preferably PB, PBS or TBS, most preferably 0.1M TBS solution;Reaction is slow
The Optimal pH of fliud flushing is 6;Optimum reacting time is 12-16 hours.
As still more preferably scheme, step d concrete operations are:In coupling medium reaction buffer, 4 DEG C
Under pH4.0-9.0, by polysaccharide-magnetic Nano microsphere couplet chemically modified obtained by step c and carrier protein coreaction 12-
24 hours;Wherein coupling medium is preferably PB, PBS or TBS, most preferably 0.1M TBS solution;The Optimal pH of reaction buffer is
6;Optimum reacting time is 24 hours.
As still more preferably scheme, isolating and purifying for step e is by coupling conjugate and unreacted polysaccharide and load
Body protein isolates and purifies, and purification process can use chromatography or ultrafiltration;It can be carried out according to the molecular size of the conjugate vaccines of acquisition
Isolate and purify, chromatography is preferably using Superdex200 solvent resistant columns, Sepharose CL-4B or Sepharose CL-6B
Carry out;And ultrafiltration is to separate conjugate and unreacted reactant using different retention molecular weight film.
The conjugate vaccines preparation can use aqua or freeze-dried.In order to strengthen its immunogenicity, adjuvant can be added, is commonly used
Adjuvant have aluminium adjuvant, such as aluminium hydroxide, aluminum phosphate, prioritizing selection aluminum phosphate of the present invention.The solvent of conjugate can be 0.2 chlorination
Sodium solution, 1 × PBS or other buffer solutions that can stablize polysaccharide or conjugate.The conjugate vaccines of the present invention are respectively made
The preparation method of agent is prepared using the conventional meanses of the art.Wherein, preferably in the presence of sugared (such as sucrose or lactose)
Freezed.
Conjugate vaccines provided by the invention can be immunized with any existing approach, including skin corium or skin are given
The forms such as medicine, intramuscular delivery.Wherein, the amount given is that those skilled in the art are confirmable according to general knowledge.
Term defines
Core VP8:Being one section in rotavirus protein VP8 has and cell surface contains sialic acid (sialic acid)
The polypeptide chain of adhesive function, usually contain 160 amino acid residues.
VP8 polypeptide chain fragments:It is less than total length VP8 polypeptide chain for any molecular weight.
VP4 polypeptide chain fragments:It is less than total length VP4 polypeptide chain for any molecular weight.
VP8 specific antigen cluster chains:Full VP8 polypeptide chains contain multiple antigenic determinants, are cut by the method for genetic recombination
Cut and be free of important amino acid, and retain the polypeptide chain containing specific antigen cluster, molecular weight is typically smaller than total length VP8 polypeptides
Chain.
VP4 specific antigen cluster chains:Full VP4 polypeptide chains contain multiple antigenic determinants, are cut by the method for genetic recombination
Cut and be free of important amino acid, and retain the polypeptide chain containing specific antigen cluster, molecular weight is typically smaller than total length VP4 polypeptides
Chain.
VP8 fusion proteins:With gene recombination method, by VP8 albumen and other soluble protein polypeptide chain amalgamation and expressions, with
Improve the solubilities of VP8 in aqueous;Or enhancing VP8 immunogenicity.
NSP4 albumen:It is non-structural protein, there is enterotoxin characteristic, molecular weight 28kDa, contain 175 amino acid.
VP8-NSP4 fusion proteins:With the method for genetic recombination, by VP8 and NSP4 polypeptide chain amalgamation and expressions, to improve VP8
Solubility in aqueous, while cause fusion protein that there is the protection antibody for stimulating body to produce anti-NSP4.
Capsular polysaccharide fragment:Will by the methods of physics (such as ultrasonic wave, particle spray), chemistry (such as acid, alkali, enzymic digestion)
Obtained by polysaccharide (the claiming full polysaccharide or original polysaccharide) degraded (depolymerization) purified in inoculum more
Bglii fragment, molecular weight are usually less than original polysaccharide.Pod membrane oligosaccharide:By physics (such as ultrasonic wave, particle spray), chemistry (such as
Acid, alkali, enzymic digestion) the methods of will be degraded by the polysaccharide (claiming full polysaccharide or original polysaccharide) that is purified in inoculum
(depolymerization) polysaccharide fragment obtained, the monosaccharide residue in molecular structure are usually less than 10.But monose is residual
The definition of radix amount is variant, and the polysaccharide chain that 20 monosaccharide residues are less than more than 10 is also turned into oligosaccharide by some documents.
Compared with prior art, the present invention has the advantage that:
1. the conjugate vaccines are the immunoconjugates containing two or more different carriers albumen, with existing pneumonia
Coccus combined vaccine is compared, and its immunogenicity is stronger, and the polysaccharide antibody of induction is horizontal to be higher than single carrier conjugates, can be wider
Cause immune response, especially infant in wealthy crowd;By reducing each carrier dosage carrier epitope can be avoided to overload;Can
Strengthen T-helper cell activity by two kinds of carriers;
2. due to having the Protein Epitopes of protectiveness also can two kinds of albumen mixing notes of induction ratio in two kinds of carrier proteins
Higher immune response when penetrating, mutually synergy, further enhance the immunogenicity of carrier protein, add body to more
The immune response of sugar;
3. the present invention it is pioneering using magnetic Nano microsphere as polysaccharide and the connector of overloading body protein, be effectively prevented from
Autoimmunity syndrome in preparation process between capsular polysaccharide and protein, it is possible to increase with reference to the yield of product, and be beneficial to product
Quality control;The space length that can effectively extend between capsular polysaccharide and carrier protein, it is more to pod membrane to reduce carrier protein
The spatial masking effect of sugar antigens epitope, be advantageous to improve the immunogenicity of capsular polysaccharide;
4.-the OH by magnetic Nano microsphere surface initiated in the preparation process of the conjugate vaccines first carries out even with polysaccharide
Connection reaction, then by couplet it is chemically modified by unreacted-OH be modified as-CHO with-the NH in carrier protein2It is coupled
With reference to associated methods more of the prior art are more stable;
5. its preparation method is simple, it is adapted to the needs of scale industrial production, does not significantly change capsular polysaccharide and carrier egg
White architectural feature.
To sum up state, conjugate vaccines preparation technology provided by the invention is simple, uses magnetic Nano microsphere sewing for attachment
Mouse Th1 type immune responses can be strengthened by closing vaccine, and the immune lasting effect of polysaccharide specificity antibody, specificity and affine
Property, it additionally can induce mouse and produce rotavirus antibody;Possesses the preventive effect of two kinds of vaccines;Therefore with very wide
Application prospect.
Brief description of the drawings
Fig. 1 is the conjugate vaccines obtained by the embodiment of the present invention 11H-NMR spectrum;
Fig. 2 is the immune response experimental result schematic diagram of the polysaccharide specificity antibody of conjugate vaccines provided by the invention;
Fig. 3 is the immune lasting effect experimental result schematic diagram of the polysaccharide specificity antibody of conjugate vaccines provided by the invention;
Fig. 4 is the rotavirus neutralization test result schematic diagram of conjugate vaccines provided by the invention.
Embodiment
The present invention is made with reference to embodiment further in detail, intactly to illustrate.Reagent used below or equipment are
Commercially available kind, unless otherwise specified, operate, will not be described here to specifications.
Below for the present invention is further illustrated in conjunction with specific embodiments, but it is not construed as limitation of the invention.
Embodiment 1
First, magnetic Nano microsphere is prepared
1. take 2.24gFeSO4-7H2O and 3.24gFeCl3-6H2O is dissolved in the dddH of 10mL and 15mL filtering deoxygenations respectively2O
In, mix after dissolving and hook, add the dddH of 100mL filtering deoxygenations2O;
2. in N2Protection under stir 5min, it is disposable to add 50mL1mol/LNaOH solution, then adjust pH value of solution to 9-
10, accelerate mixing speed to 200-250r/min, continuously stir 30min;
3. reaction vessel is transferred in 65-70 DEG C of water-bath, continue in N2Protection under stirring ageing 30min;
4. reaction, which finishes, is settled to 100mL, micro- Microscopic observation magnetic particle synthesizes situation;
5. 400mgPLGA is dissolved in 10mLEA solvents as oil phase (O), the above-mentioned magnetic particle solution conducts of 3mL are added
Interior aqueous phase (W1), just emulsificationization is carried out in ice-water bath using ultrasonic cell disintegration instrument (120W, 60s) and prepares colostrum, then will just
Breast pours into a certain amount of aqueous solution (outer aqueous phase, W containing 15g/LPVA and 0.9% (ω) NaCl2), magnetic agitation (300r/min,
2min) prepare pre- double emulsion (W1/0/W2), then pre- emulsion is poured into the storage tank of fast film emulsification, with certain N2Pressure by its
SPG films are pressed through repeatedly, obtain the nanoparticle emulsion drop of uniform particle diameter.In addition, unspent nanoparticle can be made into it is freeze-dried
Continue to employ.
Or by taking Fe3O4Magnetic particle is added with 50mL with absolute ethyl alcohol as isometric, after ultrasonic activation 30min, puts 60
In DEG C water-bath, 10mLPELA is slowly added dropwise to magnetic Nano microsphere progress-NH2It is terminal-modified and PELA is wrapped in Fe3O4Magnetic
Outside property particle, stirring reaction 10h, is made magnetic Nano microsphere under nitrogen protection;After completion of the reaction, washed with 50mL absolute ethyl alcohols
Paint 3 times, then after washing paint three times with 0.01MPBS, it is settled to 50mL, micro- Microscopic observation magnetic bead is modified situation, micro- to magnetic Nano
Ball surface-NH2End is changed to-OH ends.
2nd, the preparation of pneumococal polysaccharide
1. choose 24 kinds of serotypes (1,2,3,4,5,6A, 6B, 7F, 8,9N, 9V, 10A, 11A, 12F, 14,15B, 17F,
18C, 19A, 19F, 20,22F, 23F, 33F) pneumococcus culture;
2. the capsular polysaccharide that antigenicity is strong in any of the above Pneumococcal serotype is purified respectively:Pneumococcus, after inactivation
Supernatant is collected by centrifugation, through being concentrated by ultrafiltration, appropriate (volume fraction 70% is separately added into according to each Pneumococcus serotypes characteristic
) pre-cooled ethanol, it is collected by centrifugation, obtains rough polysaccharide;Rough polysaccharide is dissolved in sodium acetate solution, then in 1: 2 ratio with cold
Phenol mixes, and removing protein is removed in centrifugation, and phenol carries 5-6 times repeatedly, collects supernatant, is dialysed with distilled water, liquid adds 2mol/L chlorine after dialysis
Change calcium solution, add ethanol stirring, centrifugation removes nucleic acid, collects supernatant, adds ethanol (final concentration 80% stirs), be collected by centrifugation
Precipitation, precipitation is washed with ethanol, acetone, is that multivalence refines capsular polysaccharide after dehydrating, is put -20 DEG C and save backup.
3rd, the preparation of rotavirus carrier protein
The preparation of rotavirus carrier protein can be found in the preparation method of a variety of recombinant proteins of the prior art, this implementation
Example uses the method referred in CN 101972475 to prepare, and can be reduced to following steps, design parameter does not repeat:
1st, the cDNA storehouses of rotavirus are established
Human rotavirus Wa strains (2018-VR, ATCC) are in MA104 cells (the monkey embryo added with 1 μ g/mL trypsase
Foetus renal cells) in, 36 DEG C of temperature expands 1 to 2 day.Low-speed centrifugal removes cell fragment, adds hydroxyapatite
(hydroxyapatite, HA) purified virus RNA into supernatant.Concretely comprise the following steps:600 μ l 6M guanidinium isothiocyanates (GITC)
Solution is added in 400 μ l culture supernatant, is mixed.Then 50 μ l (two drops) HA suspension is added, is turned upside down at room temperature
20 minutes are placed so as to by nucleic acid absorption to HA on mixing test tube or earthquake device.Centrifuged 1 minute with 13,000g, in discarding
Clear liquid.RNA-HA is washed with 1mL 10mM potassium phosphates pH6.8 twice.The 200mM potassium phosphate pH6.8 solution for adding 40 μ l is tied from HA
Eluted rna on crystalline substance, 3 minutes RNA for collecting purifying are centrifuged with 13000g.Reverse transcription-polymerase chain reaction is carried out immediately, by sample
Product solution is stored in -20 DEG C.
In order to which amplification coding has a VP4 genes of Wa strain VP8 albumen, design of primers is as follows:Sense primers
HWaVP4pET28:5 '-TTACATATGGCTTCGCTCATTTATAG-3 ', anti-sense primer AHWaVP4 ρ ET28:5’-
CCGGATCCCTAGTCTTCATTAACTTGTGCT-3’。
With SuperScriptOne-StepRT-PCR systems, RT- is carried out containing PlatinumTaqDNA polymerase kits
PCR is expanded.
Comprise the following steps that:The RNA of 8 μ l purifying is added to DMSO added with 4 μ l, 2 μ l 20mMHWaVP4 ρ ET28 and
The 0.2-mL test tubes of AHWaVP4pET28 primers, heat 2 minutes at 94 DEG C, annealed on ice bath.Then containing for 86 μ l is added
0.2mM various dNTP, 1.5mM MgCl2With 2 μ l reverse transcriptase and Taq enzyme reaction mixture.Carried out such as in PCR instrument
The reaction of lower condition:42 DEG C hatch 60 minutes, are reacted subsequently into the PCR in 35 cycles, 94 DEG C 30 seconds, 42 DEG C 50 seconds, 72 DEG C
70 seconds, last 72 DEG C hatched 7 minutes.RT-PCR amplified productions are purified on GFX posts.
PCR primer is incorporated into pGEM-TEasy carrier with the method that is directly connected to.The amplification plasmid of structure is transformed into
To in Competent cells E.coliTop10.With WizardSVMiniprepDNA, the conversion bacterium colony of the positive is selected, is trained in LB
Support in base and expand bacterium, collecting bacterial body, purification system recombinant dna plasmid.The plasmid for containing VP8 protein expression sequences is referred to as
PGEM-TWaVP8, plasmid is stored in -20 DEG C.
2nd, pET28aWaVP8 expression total length VP8 plasmids are built
With nucleic acid restriction endonuclease NdeI and BamHI come pGEM-TWaVP8 made from digestion step 1, to obtain VP8 bases
Because of insetion sequence.Equally with nucleic acid restriction endonuclease NdeI and BamHI come digested vector pET28a (+).Add 10 μ g VP8
Gene inserts, T4DNA ligases and the pET28a (+) that cuts through are in test tube, in 16 DEG C of reactions overnight.What the structure was completed
Plasmid is referred to as pET28aWaVP8.The plasmid expression come out albumen contain 6- histidine marks (hexa-histidinetag, 6
× His-Tag), and have thrombin recognition site (thrombinrecognitionsite) in 5 ' ends.
PET28aWaVP8 plasmids are transformed into competent cells E.coliTOP10, this is cloned in 50 μ g/mL's
The LB culture mediums ware screening pET28aWaVP8 positive bacterium colonies of kanamycins (Kanamycin).It is inoculated in LB nutrient solutions and carries out
Amplification, preserve below -20 DEG C of strain of expression, while ρ ET28aWaVP8 plasmids are extracted from bacterium, it was demonstrated that VP8 nucleotide sequence
(SEQIDNO:1).
3rd, expression restructuring VP8 albumen
1) pET28aWaVP8 plasmids made from step 2 are transformed into BL21 (DE3) competent cells by, and inoculation is thin
Born of the same parents are to 50 μ g/mL kanamycins LB culture dishes, in CO at 37 DEG C2In incubator overnight.
2) picks out a bacterium colony, is inoculated into 10 milliliters of kanamycins LB nutrient solution (1% tryptoses containing 50 μ g/mL
Peptone, 0.5% yeast extract, 1%NaCl, pH7.5) in expand, in 37 DEG C of overnight incubations.
3) turns nutrient solution to be inoculated into 100 milliliters of 50 μ g/mL kanamycins LB nutrient solutions, continues to cultivate.Treat absorbance
When 600nm OD reaches 1.0, nutrient solution turn is inoculated into 6 and is raised in 50 μ g/mL kanamycins LB nutrient solutions, is continued at 37 DEG C,
Shake in fast 200rpm shaking table and cultivate, when absorbance 600nm OD reaches 0.6~0.8, add 0.3mM IPTG (isopropyls
Base-β-D- thiogalactosides) induction VP8 expression.
4) is under identical condition of culture, after inducing 4 hours, under 4000g, after 10 DEG C centrifuge 20 minutes, to collect bacterium
Body.
5) by bacterial suspension in 20mL 1 × PBS solution, after crushing bacterium with French press filtration kettle (Frenchpress),
Under 10000g, centrifuged 30 minutes at 10 DEG C, abandon supernatant, collect the inclusion body of precipitation.Before being further purified, storage bag
Contain body in -40 DEG C.
4th, VP8 albumen is purified from inclusion body
1) weighs the VP8 inclusion bodys 0.5 gram (weight in wet base) of step 3 preparation, with cleaning buffer solution (10mMTris, 100mM phosphorus
Phthalate buffer, 2Murea, pH8.0) suspension inclusion body, it is incubated 30 minutes, is centrifuged 10 minutes with 10,000g at room temperature, is received
Collect inclusion body.Above step is repeated three times except the foreign protein to depollute.
2) by inclusion body precipitation be dissolved in dissolving buffer solution (10mMTris-HCl, 100mM phosphate buffer, 8M urea,
PH8.0, abbreviation buffer B) in, it is incubated 1 hour in stirring on ice.Centrifuged 30 minutes with 16,000g, collect supernatant, abandoned
Insoluble sediment.
3) with fixing metal ions affinity chromatography chromatography (IMAC) purifying His-tagged restructuring VP8 albumen.
Specific method is:SepharoseFF glue will be chelated in advance in 0.1M NiSO4 solution, mixing is flat at room temperature
Weighing apparatus, shake for several times so that Ni2+After being sequestered on glue, Ni-Sepharose is cleaned twice with deionized water, removes what is do not chelated
Ni2+Ion.By colloidal suspension in buffer B, IMAC posts are made in dress post., then will be dissolved with VP8 with buffer B pre-balance post
The buffer B upper prop of albumen, at room temperature, treat that solution balances the His-tag and Ni caused for 30 minutes in restructuring VP8 albumen on post
Ionic adsorption.Post is washed with buffer B, post is washed with the imidazole buffer Bs containing 10mM.Further use buffer solution C
(10mMTris-HCl, 100mM phosphate buffer, 8M urea, pH6.3) washes post.Then (contained with elution buffer
100mMEDTA, 2mM beta -mercaptoethanol and buffer B) elution VP8 albumen.
4) collects the eluent containing VP8, is transferred in bag filter in the TBS containing 20mM beta -mercaptoethanols 1 and 8M urea
(pH4.0) dialysed in, and gradually reduce the concentration (i.e. 8,6,4,2, and 1M) of urea, the dialysed overnight in 4 DEG C.Then containing
Dialyse twice in the TBSpH5.5 solution of 2mM beta -mercaptoethanols, finally dialysed in TBS solution.According to restructuring VP8 albumen sources
Strain it is different, finally to be dialysed.
4th, the preparation of Pneumococal surface protein A (rPspA)
PspA albumen is cloned into Escherichia coli to be expressed and isolated and purified, specifically included:
1. the optimization of target gene and the structure of recombinant expression plasmid
PspA gene orders (GI is obtained in GenBank:193804931) and optimize, plus being carried out after His labels
Full genome synthesizes, by the sequence of synthesis after Sac I and Nde I double digestions, the expression vector of directed cloning to same double digestion
In pET-30a (+), transformed competence colibacillus e. coli bl21 Star (DE3), 37 DEG C are incubated overnight, picking positive monoclonal bacterium colony,
Plasmid is extracted after amplification cultivation, is identified with Nde I and Sac I double digestions, and send sequencing, correct recombinant expression plasmid will be sequenced
It is named as pET-30a-rPspA.
2. induced expression and the purifying of recombinant protein
Recovery engineering bacteria, 2 × LB culture mediums are inoculated with 1: 100 ratio, expands culture under 37 DEG C of 237r/min, works as bacterium
When body value is about 12, IPTG to final concentration of 1mmol/L, 37 DEG C of induction 4h are added, sampling carries out SDS-PAGE analysis centrifugal receipts
Collection induction thalline, adds physiological saline and washing 2 times is resuspended, and 05mol/LNaCl5mmol/L miaows are added with 1: 10 (g/mL) ratio
Thalline is resuspended in azoles 20mmol/LPB (pH7.4) buffer solution, ultrasonic disruption thalline, 8000 × g centrifugation 40min, collects supernatant,
Purified in nickel ion chromatographic column, by specification operation purified product and analysis by carrier pET-30a (+) conversion it is big
Enterobacteria BL21Star (DE3) whole cell (control) and electrotransfer is fine to nitric acid after SDS-PAGE is separated by upper step purification of samples
Tie up on plain film, 2h is closed with 5% skimmed milk power shaking table slight oscillatory;His mouse source monoclonal antibody (1: 800 dilution) is added, 4 DEG C overnight;
TBST is cleaned 3 times, is added the sheep anti-mouse igg (1: 2000 dilution) of HRP marks, is incubated at room temperature 1h;Washing 3 times, DAB colour developings.
5th, the preparation of people's Rotavirus Vaccine
1. polysaccharide-magnetic Nano microsphere coupling
Under 0.1MTBS solution buffer solutions, pH6.0 adds obtained one or more capsular polysaccharides of above-mentioned steps and magnetic is received
Meter Wei Qiu, in the present embodiment using 13 valency capsular polysaccharides (1,3,5,6A, 6B, 7F, 9V, 14,18C, 19A, 19F and 23F), pod membrane
The mass ratio of polysaccharide and magnetic Nano microsphere is 1: (0.5-1), reacts 6-24 hours at room temperature;The mass ratio wherein optimized is
1: 1, aldolisation 16 hours at room temperature.After reaction terminates, fully dialysed with bag filter, it is micro- to remove unreacted magnetic Nano
Ball.
2. coupling is modifies
Step 1 polysaccharide-magnetic Nano microsphere couplet 30mL is taken, 2mL25% glutaric acids are slowly added dropwise under stirring condition,
200r/min stirring reactions 6 hours;After completion of the reaction, after being washed three times with 0.01MPBS, 30mL, micro- Microscopic observation are settled to
Magnetic Nano microsphere be modified situation so that polysaccharide-magnetic Nano microsphere couplet surface with polysaccharide reaction-OH be not modified as-
CHO;N2, 4 DEG C save backup.
3. it is coupled altogether with PspA carrier proteins and rotavirus protein
Under 0.1MTBS solution buffer solutions, 4 DEG C, under pH4.0-9.0, by modified polysaccharide-magnetic Nano microsphere respectively with
Rotavirus protein and PspA albumen coreaction (to ensure enough carrier protein and magnetic Nano microsphere, used for 24 hours
Nano-carrier albumen addition is measured, as mass ratio uses polysaccharide: magnetic Nano microsphere: PspA: rotavirus protein=1: 1: 2:
2)。
4. people's Rotavirus Vaccine isolates and purifies
Isolated and purified with Superdex200 solvent resistant columns (2.6cm × 60cm), eluent is that 20mM phosphoric acid delays
Fliud flushing (pH7.4), flow velocity 3mL/min.Collect the eluting peak corresponding to polysaccharide-magnetic Nano microsphere-complex carries albumen.
The composition analysis of obtained people's Rotavirus Vaccine
With1H-NMR carries out detecting people's Rotavirus Vaccine, and testing result is shown in Fig. 1.It is as shown in figure 1, more with pod membrane
Glycan molecule is compared, and characteristic peak occurs at 0.4-1.4ppm in conjugate, corresponding to the aliphatic chain amino acid residue of carrier protein.
Occurs the characteristic peak of the aromatic amino acid residue corresponding to carrier protein at 7.2ppm.This show capsular polysaccharide molecule into
It has been coupled two kinds of carrier proteins of rotavirus protein and PspA carrier proteins work(.Occur corresponding to succinyl at 6.2ppm
The characteristic peak of imines, this shows to contain succinimide in the connecting bridge of polysaccharide conjugate vaccine.In addition, 5.2,1.6,3.6 outlets
PELA characteristic peak proves magnetic Nano microsphere PELA as attachment.Therefore, capsular polysaccharide is combining two kinds of carrier proteins
Front and rear, its structure does not occur substantially to change.
It is the molecular weight distribution situation that SEC-MALLS methods detect GL-PP conjugate by CL-4B;By immune double
The method of expansion determines the albumen in GL-PP conjugate and more sugar types using different antibody serums;Detected by anthrone method
The polyoses content of GL-PP conjugate;Lowry methods protein content detects the total protein content of GL-PP conjugate, then passes through
The GL-PP that conjugate is calculated is combined than (Ratio);Rotavirus protein, PspA protein concentrations pass through ELISA
Detection.As a result show:In the people with Rotavirus Vaccine stoste, the concentration ratio of each material is about:Polysaccharide: magnetic Nano is micro-
Ball: PspA: rotavirus protein=1: 1: 1: 1).
Comparative example 1
This comparative example differs only in embodiment 1:Nonmagnetic nanoparticle is as connector in obtained vaccine, and
And the method by referring in the prior art complex carries albumen and polysaccharide is conjugated to obtain.
Comparative example 2
This comparative example differs only in embodiment 1:Without PspA carrier proteins in obtained vaccine, only with polysaccharide-
Magnetic nanometer particles-rotavirus carrier protein behaviour Rotavirus Vaccine.
Embodiment 2
The present embodiment differs only in embodiment 1:The people is colyliform disease with the carrier protein of Rotavirus Vaccine
Poisonous carrier albumen and tetanus toxoid carrier albumen.
Theoretical error scope be present with the acquired results of embodiment 1 in the composition analysis result of obtained people's Rotavirus Vaccine
Interior uniformity.
Embodiment 3
The present embodiment differs only in embodiment 1:The people is colyliform disease with the carrier protein of Rotavirus Vaccine
Poisonous carrier albumen and bloodthirsty Bacillus influenzae surface protein HiD.
Theoretical error scope be present with the acquired results of embodiment 1 in the composition analysis result of obtained people's Rotavirus Vaccine
Interior uniformity.
Embodiment 4
The present embodiment differs only in embodiment 1:Connector is PLGA magnetic nanoparticles.
Theoretical error scope be present with the acquired results of embodiment 1 in the composition analysis result of obtained people's Rotavirus Vaccine
Interior uniformity.
Embodiment 5
The present embodiment differs only in embodiment 1:Connector is PEG magnetic nanoparticles.
Theoretical error scope be present with the acquired results of embodiment 1 in the composition analysis result of obtained people's Rotavirus Vaccine
Interior uniformity.
Vaccine evaluation
Assessment experimental evaluation embodiment 1~7 using vaccine routine potency such as immunogenicities and the institute of comparative example 1~2 below
Obtain the immune effect of vaccine:
A. people is with Rotavirus Vaccine immunogenicity experiments
The female Blab/C mouse of 100 5 week old are chosen, body weight is 15-22 grams.Be randomly divided into 10 groups, i.e., embodiment 1~
7th, comparative example 1~2 and positive controls (Prevnar 13), every group of 10 mouse.Intraperitoneal injection, every per injection are 5 micro-
Gram, inject 1 time weekly, co-injection 3 times.Posterior orbit takes blood within 21 days.With ELISA method detection mice plasma moderate resistance capsular polysaccharide
IgG, IgG1 and IgG2a.Experimental result is shown in Table 1
Table 1
As shown in table 1, the people of gained can be obviously improved antibody titer (p < with Rotavirus Vaccine in embodiment 1~7
0.0001**), as shown in Fig. 2 and being substantially better than comparative example 1 and comparative example 2 and positive controls;As can be seen here, using double
Carrier protein and can significantly increase that Th1 types are immune with Rotavirus Vaccine with people obtained by magnetic Nano microsphere and pneumonia polysaccharide should
Answer, and immune effect is substantially better than obtained by single carrier protein without nano-magnetic microsphere connector and comparative example 2 of comparative example 1
People's Rotavirus Vaccine;But it will also realize that according to the immune response result of the gained of embodiment 1~5, be complex carries by PspA or HiD
The immune response effect of one of albumen is preferable, and PELA and PLGA is good compared with PEG immune responses effect in magnetic nano-carrier.
B. the immune lasting effect of polysaccharide specificity antibody, specificity and affinity experiment
Once tested with Rotavirus Vaccine with embodiment 1, comparative example 1 and 2 and positive control income earner respectively.
1st, lasting effect is immunized
The titre of polysaccharide specificity antibody in latter 20 weeks is immunized by determining three pins, to study exempting from for polysaccharide specificity antibody
Epidemic disease lasting effect.Fig. 3 is the immune lasting effect schematic diagram, as shown in figure 3, its polysaccharide specificity IgG titres are relatively low, with injection
Time increases and gradually reduced, and the 4th Zhou Houyi can not be detected.Polysaccharide specificity IgG titres are low caused by comparative example 1 and 2
In 1 group of embodiment, and it is higher than positive controls.Polysaccharide specificity IgG titres in the 2nd Zhou Dafeng, in the 4-20 weeks gradually under
Drop, the decrease speed of wherein positive controls are most fast.After 18th week, 1 group of embodiment, comparative example 1, comparative example 2 and positive control
The polysaccharide specificity IgG titres of group are 20%, 15%, 12% and the 10% of its peak value respectively.Therefore, people provided by the invention uses
Rotavirus Vaccine can strengthen the immune lasting effect of polysaccharide specificity antibody.
2nd, specificity and compatibility
Added into 200 times of the PS-TT groups diluted, PS-PLGA-TT groups and PS-PELA-TT group mice plasmas different amounts of
Capsular polysaccharide, the antibody level of mice plasma moderate resistance capsular polysaccharide is detected with ELISA method, the results are shown in Table 2.
Table 2
As shown in table 2, with the increase of polysaccharide addition, in the orifice plate of polysaccharide specificity antibody binding 96 ability of polysaccharide by
Gradually reduce.When the polysaccharide of addition reaches 20 μ g, the Disability of antibody binding polysaccharide.This shows people provided by the present invention
Anti- capsular polysaccharide antibody can specifically combine capsular polysaccharide caused by Rotavirus Vaccine inducing mouse.
The Antibody Avidity of anti-capsular polysaccharide is determined with ammonium thiocyanate.The polysaccharide of capsular polysaccharide group (negative control) is special
Property antibody index of affinity is 1.18mol/L, and positive controls, 1 group of comparative example, the antibody of 1 group of 2 groups of groups of comparative example and embodiment
Index of affinity is respectively 2.65mol/L, 2.80mol/L, 3.02mol/L and 3.21mol/L.This shows that people provided by the invention uses
Rotavirus Vaccine can significantly improve the affinity of polysaccharide specificity antibody.
C, rotavirus neutralization test result
Using mice serum each group (embodiment 1~5,1 group of comparative example and comparative example 2 made from method difference in embodiment 1
Group inject a pin, two pins and three pins respectively) each mice serum respectively take 10 μ L mix, for neutralization test Sample serum.
The neutralization test of anti-WaVP8 antibody uses BSC-1 cells on microplate (microplate) caused by injection small white mouse
Carry out.After heat inactivated serum is serially diluted, after being mixed with 100TCID50 Wa rotavirus strains, in 4 DEG C of cultures
1 hour.Then BSC-1 cells are inoculated on microplate, hatched 1 hour.DMEM (being free of serum) is added to be added to each hole, 37 DEG C
Hatching 1 hour.Finally, dilution antiserum can prevent the concentration that rotavirus cytopathic effect (CPE) occurs from being dripped to neutralize
Degree.Polysaccharide control group serum is used as negative control.Experimental result is shown in Table 3 and Fig. 4.
Table 3:People is injected with Rotavirus Vaccine in small white mouse antibody and Rotavirus Wa strain strain result of the test
As shown in table 3, it is better than contrast with rotavirus positive effect in the income earner's Rotavirus Vaccine of embodiment 1~5
Example 1 and comparative example 2, significantly can induce rotavirus antibody to produce;In addition, in embodiment 1,3 and 5 and rotavirus effect will
It is in other words, preferable for the neutralization virus effectiveness of one of complex carries albumen by PspA or HiD better than other embodiment, and magnetic is received
PELA and PLGA is good with virus effectiveness compared with PEG in meter Zai Ti..
Finally be necessary described herein be:Above example is served only for further detailed to technical scheme work
Ground explanation, it is impossible to be interpreted as limiting the scope of the invention, those skilled in the art is according to the above of the invention
Some the nonessential modifications and adaptations made belong to protection scope of the present invention.
Claims (10)
1. people's Rotavirus Vaccine, it is characterised in that:The people is multivalent pneumococcal polysaccharide and two with Rotavirus Vaccine
People's Rotavirus Vaccine that kind or two or more carrier proteins form through connector, wherein, connector is that magnetic Nano is micro-
Ball, the one in two or more carrier protein is rotavirus protein.
2. people's Rotavirus Vaccine according to claim 1, it is characterised in that:The micro- magnetic particle of the magnetic Nano
It is core positioned at the inside of nanoparticle, high polymer material is wrapped in the outside of magnetic particle.
3. people's Rotavirus Vaccine according to claim 2, it is characterised in that:High polymer material is boiomacromolecule material
Material, selected from chitosan, polyethylene glycol, Poly(D,L-lactide-co-glycolide (PLGA), PLA-PEG copolymer
(PELA) one or more of mixtures in.
4. people's Rotavirus Vaccine according to claim 1, it is characterised in that:Multivalent pneumococcal polysaccharide and two kinds of loads
The mass ratio of body protein is (0.5~2):1.
5. people's Rotavirus Vaccine according to claim 1, it is characterised in that:In two or more carrier protein
Another carrier protein be selected from diphtheria toxoid, tetanus toxoid, carrier protein CRM197, bloodthirsty Bacillus influenzae surface protein
HiD, pertussis Prn surface proteins, pertussis Fha antigens and/or Pneumococal surface protein A (rPspA).
6. people's Rotavirus Vaccine according to claim 1, it is characterised in that:Rotavirus protein is recombined human colyliform
Virus protein.
7. people's Rotavirus Vaccine according to claim 1, it is characterised in that:Recombined human rotavirus protein is P bases
Because of the partial amino-acid series or complete sequence of type rotavirus protein.
8. people's Rotavirus Vaccine according to claim 1, it is characterised in that:The virus of recombined human rotavirus protein
Strain is one kind in P genotype rotavirus strain P [8], P [4], P [6] or P [11].
9. the preparation method of any people's Rotavirus Vaccine of claim 1~8, it is characterised in that:By multivalence pneumonia ball
Granulose forms with nanoparticle through coupling respectively with two kinds or more of carrier protein.
10. the preparation method of people's Rotavirus Vaccine according to claim 9, it is characterised in that specifically include following
Step:
A) capsular polysaccharide on difference separating-purifying various serotype pneumococcal capsule;
B) simultaneously the rotavirus carrier protein selected by separating-purifying and another carrier protein are prepared respectively;
C) various capsular polysaccharides and nanoparticle are coupled into polysaccharide-nanoparticle couplet respectively;
D) polysaccharide-nanoparticle couplet is combined with rotavirus carrier protein and another carrier protein couplet respectively again;
E) couplet obtained by purification procedures d) into the people with Rotavirus Vaccine stoste.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410359131 | 2014-07-25 | ||
CN2014103591319 | 2014-07-25 | ||
CN201410487361.3A CN104258387B (en) | 2014-07-25 | 2014-09-23 | People's Rotavirus Vaccine and preparation method thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410487361.3A Division CN104258387B (en) | 2014-07-25 | 2014-09-23 | People's Rotavirus Vaccine and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107412765A true CN107412765A (en) | 2017-12-01 |
CN107412765B CN107412765B (en) | 2020-08-11 |
Family
ID=52150043
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410487361.3A Active CN104258387B (en) | 2014-07-25 | 2014-09-23 | People's Rotavirus Vaccine and preparation method thereof |
CN201710278659.7A Active CN107412765B (en) | 2014-07-25 | 2014-09-23 | Human rotavirus vaccine and preparation method thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410487361.3A Active CN104258387B (en) | 2014-07-25 | 2014-09-23 | People's Rotavirus Vaccine and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN104258387B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111617241A (en) * | 2020-06-08 | 2020-09-04 | 扬州大学 | Chitosan-modified nano-enzyme mucosal immune adjuvant, influenza mucosal vaccine and preparation method thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108721616B (en) * | 2018-09-05 | 2019-08-16 | 广州渔跃生物技术有限公司 | A kind of avian pasteurella multocida capsular polysaccharide-protein conjugate vaccines and preparation method thereof |
CN113480617A (en) * | 2021-07-09 | 2021-10-08 | 山东威高利彤生物制品有限公司 | Rotavirus strains and their use as vaccines |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101972475A (en) * | 2010-04-12 | 2011-02-16 | 李建平 | Bacterial polysaccharide-protein conjugate vaccine and preparation method thereof |
CN102485274A (en) * | 2010-12-01 | 2012-06-06 | 吉林大学 | Preparation method and use of poly(lactic-co-glycolic acid) (PLGA) microspheres as nucleic acid vaccine vectors |
CN103893751A (en) * | 2014-03-26 | 2014-07-02 | 天津康希诺生物技术有限公司 | Pneumococcal polysaccharide and protein conjugated vaccine and preparation method thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2627233T3 (en) * | 2007-10-12 | 2017-07-27 | Massachusetts Institute Of Technology | Vaccine Nanotechnology |
GB201003088D0 (en) * | 2010-02-24 | 2010-04-14 | Univ Exeter | Method for the preparation of a novel nanoparticle conjugate |
-
2014
- 2014-09-23 CN CN201410487361.3A patent/CN104258387B/en active Active
- 2014-09-23 CN CN201710278659.7A patent/CN107412765B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101972475A (en) * | 2010-04-12 | 2011-02-16 | 李建平 | Bacterial polysaccharide-protein conjugate vaccine and preparation method thereof |
CN102485274A (en) * | 2010-12-01 | 2012-06-06 | 吉林大学 | Preparation method and use of poly(lactic-co-glycolic acid) (PLGA) microspheres as nucleic acid vaccine vectors |
CN103893751A (en) * | 2014-03-26 | 2014-07-02 | 天津康希诺生物技术有限公司 | Pneumococcal polysaccharide and protein conjugated vaccine and preparation method thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111617241A (en) * | 2020-06-08 | 2020-09-04 | 扬州大学 | Chitosan-modified nano-enzyme mucosal immune adjuvant, influenza mucosal vaccine and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN104258387A (en) | 2015-01-07 |
CN104258387B (en) | 2018-07-20 |
CN107412765B (en) | 2020-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6994453B2 (en) | Immunogenic compositions containing conjugated capsule saccharide antigens, kits containing them and their use | |
JP2023065429A (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
CN101972475B (en) | Bacterial polysaccharide-protein conjugate vaccine and preparation method thereof | |
CN104225589B (en) | A kind of conjugate vaccines and preparation method thereof | |
ES2535080T3 (en) | Debugging processes to obtain Streptococcus cps | |
WO2015144031A1 (en) | Pneumococcus polysaccharide protein conjugated vaccine and preparation method therefor | |
CN104582718B (en) | Immunogenic composition | |
CN102068690A (en) | Polyvalent pneumococcal capsular polysaccharide conjugate vaccine and preparation method thereof | |
CN103394082B (en) | Multivalent immunogenic composition | |
CN104258387B (en) | People's Rotavirus Vaccine and preparation method thereof | |
CN104606674B (en) | Rotavirus GL-PP combined vaccine and preparation method thereof | |
CN104208671B (en) | A kind of pneumonia multivalence combined vaccine and preparation method thereof | |
CN104189901B (en) | A kind of pneumococcus conjugate vaccines and preparation method thereof | |
CN107151270B (en) | Recombinate Δ fHbp-NadA fusion protein carriers and its preparation method and application | |
CN108619508A (en) | A kind of season influenza-RSV- epidemic meningitis-pneumococcus combined vaccine based on recombinant vector albumen | |
CN108295252A (en) | A method of preparing rabies combined vaccine | |
CN106075430A (en) | Multivalent pneumococcal ACYW135 meningococcus combined vaccine | |
CN106075420A (en) | Multivalent pneumococcal Type B hemophilus influenza combined vaccine | |
CN105399802A (en) | Type A foot-and-mouth disease genetic engineering multi-epitope protein and vaccine | |
CN101675994A (en) | Therapy vaccine preparation | |
CN106109486A (en) | A kind of compositions and preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221229 Address after: Building A9-2, Small and Medium Enterprises Park, Biomedical Industrial Park, No. 858, Gaoxin Avenue, Donghu High tech Zone, Wuhan City, 430206, Hubei Province Patentee after: BRAVOVAX Co.,Ltd. Patentee after: SHANGHAI BOWO BIOTECHNOLOGY Co.,Ltd. Address before: 430075 building a9-2, SME Park, biomedical industrial park, No. 858, Gaoxin Avenue, Donghu high tech Zone, Wuhan City, Hubei Province Patentee before: BRAVOVAX Co.,Ltd. |
|
TR01 | Transfer of patent right |